Submitted as a patient-authored case study to Noor Journal of Complementary and Contemporary Medicine Author:  Sylvia D. Barkley, MSSW, LCSW - Correspondence:   Sylviadepriest@gmail.com Abstract Background: Autoimmune thyroid diseases, including Graves’ disease and Hashimoto’s thyroiditis, are among the most commonly encountered autoimmune conditions, yet many patients experience diagnostic delays, persistent symptoms, and limited therapeutic success within conventional care frameworks. This patient-authored case report presents a longitudinal recovery narrative highlighting the role of functional medicine in diagnosing and managing complex autoimmune overlap and associated gastrointestinal immune dysfunction. Case Summary: A 30-year-old woman was diagnosed with Graves’ disease after months of fatigue, joint pain, and neurological symptoms. Conventional treatment with levothyroxine failed to stabilize thyroid function or alleviate systemic symptoms. Functional medicine intervention, emphasizing immune modulation, gut restoration, and environmental detoxification, led to laboratory-confirmed remission of Graves’, improvement in Hashimoto’s markers, and discontinuation of multiple long-term medications. Notable findings included undiagnosed selective IgA deficiency, gastrointestinal pathogen burden, and reactivation of Epstein-Barr virus, all addressed through integrative therapies such as low-dose naltrexone, BPC-157, herbal antimicrobials, and lifestyle changes. Conclusion: This case illustrates the potential value of personalized, systems-based approaches in autoimmune care, particularly for patients unresponsive to standard endocrine therapies. Functional medicine strategies targeting gut-immune interactions and immune restoration may offer a path to remission and long-term stability in complex autoimmune syndromes. Keywords:  Graves’ disease, Hashimoto’s thyroiditis, functional medicine, IgA deficiency, low-dose naltrexone, autoimmune overlap, BPC-157, gut-immune axis, Epstein-Barr virus, integrative care 1. Introduction: When the Diagnosis Finds You In March 2018, after months of vague and worsening symptoms that left my primary care provider (PCP) unsure, I was referred to an internist. That visit, a thorough hour-long conversation coupled with a fresh review of labs, led to a diagnosis that changed my life: Graves’ disease . A confirmatory blood test sealed the result. Looking back, I now realize how fortunate I was. Most people with autoimmune thyroid disorders see an average of seven physicians before receiving an accurate diagnosis. I saw just two. But that early stroke of fortune would soon be eclipsed by a cascade of dismissals, persistent symptoms, and treatment plans that failed to address the full scope of what my body was going through. 2. Conventional Treatment: Plateau and Frustration After my diagnosis, I was referred to an endocrinologist. Despite regular dose adjustments of levothyroxine every four weeks, my thyroid labs never truly stabilized. The endocrinologist repeatedly suggested radioactive iodine ablation to “calm down” the Graves’ antibodies, but I declined. I couldn’t make sense of destroying a gland I would still have to medicate indefinitely. By July 2018, my body was unraveling. I was constantly exhausted. My thoughts were clouded with brain fog. My joints ached so severely that I occasionally relied on a cane just to move around. At just 30 years old, I was being told to "learn to live with it." I pushed back. I insisted my Vitamin D and C-reactive protein (CRP) levels be tested. They revealed profound dysfunction: Vitamin D was critically low, and my CRP was elevated beyond measurable thresholds. 3. Functional Medicine: A Different Philosophy of Healing At the edge of frustration and despair, I began searching for alternatives. My mother and I explored options beyond conventional care—even considering cross-border treatment in Mexico for therapies unavailable in the United States. But practicality prevailed. I was newly married, building a career, and needed a solution closer to home. After much research, I found a physician practicing what was called functional medicine —a field focused on identifying and treating the root causes of disease, rather than just suppressing symptoms (4). During my first appointment with him, we spoke for over an hour. He listened carefully to my history and reviewed my labs. Then he said something that would become a turning point: “I suspect you have both Graves’ and Hashimoto’s disease. It’s rare, but not unheard of.” Comprehensive antibody testing confirmed his suspicion. Unlike previous providers, he did not blame my thyroid. “Your thyroid is not the problem,” he explained. “It’s your immune system attacking it.” Instead of prescribing another round of levothyroxine, he started me on low-dose naltrexone (LDN) —a therapy aimed at modulating immune response (1). Within a month, my thyroid labs normalized for the first time in years. We went deeper. He ordered stool, urine, breath, and blood tests to evaluate my digestive health, hormones, and inflammation. We discovered significant gastrointestinal dysregulation. Despite having had allergy tests before, new methods revealed numerous food sensitivities that had never been identified—mild but persistent reactions that were likely contributing to systemic inflammation. 4. Remission, Recurrence, and Rediscovery Over the next five years, I remained under his care. My Graves’ disease went into remission. My Hashimoto’s antibody levels dropped. I felt better—stronger, clearer, more resilient. He discontinued my birth control, which he believed was worsening my hormonal imbalance, and prescribed targeted supplements to fill the metabolic gaps my body wasn’t meeting on its own. To address inflammation and high CRP, he introduced me to a peptide therapy— BPC-157 , a compound showing promise in gut healing and systemic repair (5). Two years ago, I began noticing a shift again. My acid reflux worsened. My anxiety intensified to the point that even simple outings overwhelmed me. I told my doctor I felt something was wrong with my thyroid again. He ran labs. Everything looked “perfect.” But I kept listening to my body. This led me to a new provider—a nurse practitioner (NP) who treats autoimmune disorders globally. His initial consultation lasted two hours. New labs revealed that my Graves’ antibodies had returned —in high amounts. Even more surprising was a finding no one else had noticed: I was profoundly IgA deficient  (3). He told me it was likely genetic and one of the lowest levels he had ever seen. He also discovered lingering traces of Epstein-Barr Virus (EBV) —a viral passenger known to trigger or worsen autoimmune conditions (2). 5. The Gut-Immune Connection: Healing from the Inside Out Knowing I lacked IgA explained a great deal: recurrent gastrointestinal infections, weak mucosal defenses, and a vulnerability to chronic immune activation (6). Treatment began with targeting my gut . I was placed on protocols to eliminate candida overgrowth, H. pylori , and parasitic infections. My provider emphasized that with such low IgA, this wouldn’t be a one-time fix. It would require repeated, seasonal interventions just to maintain balance. At the same time, we made sweeping changes to my environment and lifestyle : Eliminated synthetic fragrances, harsh cleaning products, and chemical-laden personal care items. Adopted a tailored supplement regimen. Replaced acid-suppressing medications with herbal alternatives. Over time, the improvements came: Acid reflux nearly resolved. Propranolol discontinued. No antibiotics or steroids for over a year. Brain fog lifted, joint pain faded. 6. A New Normal: Not Cured, But Empowered I still have autoimmune disease. I still have low IgA. But I am no longer helpless. I’ve learned to support my body instead of overriding its signals. Twice a year, I proactively treat my gut to keep infections in check. I take the supplements my body needs rather than pharmaceuticals that only suppress symptoms. I’ve found peace in structure, and clarity in simplicity. What functional medicine gave me was not a miracle cure, but something more sustainable: agency, understanding, and a plan . 7. Commentary: A Case for Personalized, Root-Cause Medicine Editor’s Note This patient-authored report reflects a growing demographic of individuals with autoimmune diseases whose conditions remain unresponsive—or worsened—under standard pharmaceutical care. Her recovery highlights three key issues: IgA Deficiency is Underdiagnosed  (3) Autoimmune Overlap Syndromes Require Nuanced Care Functional Medicine Offers Plausible Alternatives  (4) Patient Authorship and Consent This article is authored by the patient, Sylvia D. Barkley, MSW , who has provided full written consent for the publication of her medical history and personal experience. Conflict of Interest The author declares no conflicts of interest and received no external funding. Acknowledgment This article was prepared with the assistance of AI for language structuring. All medical claims are supported by peer-reviewed references, which were validated for accuracy. The content was reviewed by the author to ensure scientific integrity. In the event of any inadvertent errors, responsibility rests with the author, and corrections will be made promptly. References Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines . 2017;5(2):16. doi: 10.3390/biomedicines5020016 [Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5504668/ ] Pender MP. CD8+ T-cell deficiency underlies the development of chronic autoimmune diseases by impairing control of Epstein–Barr virus infection. Autoimmune Diseases . 2012;2012:189096. doi: 10.1155/2012/189096 [Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3270541/ ] Yel L. Selective IgA deficiency. Journal of Clinical Immunology . 2010;30(1):10–16. doi: 10.1007/s10875-009-9357-x [Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC2838213/ ] Bland JS. Functional medicine past, present, and future. Journal of the American College of Nutrition . 2022;41(1):1–9. doi: 10.1080/07315724.2021.1999450 [Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9173848/ ] Ożwiak J, Świątkiewicz I, Gadomska A, et al. Multifunctionality and possible medical application of BPC-157. Pharmaceutics . 2025;18(2):185. doi: 10.3390/pharmaceutics18020185 [Available from: https://www.mdpi.com/1424-8247/18/2/185 ] Fasano A. Leaky gut and autoimmune diseases. Clinical Reviews in Allergy & Immunology . 2012;42(1):71–78. doi: 10.1007/s12016-011-8291-x [Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4284326/ ]

A newly described condition by Hanna Saadah, MD, FACP . Republished with permission from the Oklahoma County Medical Society Bulletin , July/August 2023. To discuss a complex neurological-cardiopulmonary-gastrointestinal disorder, I begin by defining two clinical types of dyspnea: A) Objective dyspnea , results from inadequate oxygen delivery, limits physical activity, and worsens with exercise. Disorders that cause objective dyspnea include obesity and diseases of the heart, lungs, blood, blood vessels, and others. B) Subjective dyspnea , occurs despite adequate oxygen delivery, does not limit physical activity, and does not worsen with exercise. Disorders that are known to cause subjective dyspnea are mostly psychogenic and include anxiety, panic, phobias, hyperventilation syndrome, sighing dyspnea syndrome, and others. C) Esophageal Pseudo-Dyspnea , the term I have chosen for this disorder, is another subjective dyspnea, but it is not psychogenic. Case Reports HS:  As a third-year medical student in 1969, I suffered from a pervasive feeling of shortness of breath, which was ameliorated by jogging. I had no cough, wheezing, heartburn, tachypnea, or chest pain, but I did have a persistent urge to take in frequent deep sighs, which did not appease my shortness of breath. That annoying shortness of breath persisted for several months, was not influenced by position, but did improve briefly with food. A medical investigation yielded no diagnosis, and no treatment was offered. As a fourth-year medical student, I happened to self-treat an isolated episode of heartburn with liquid antacid and noticed that it also relieved my shortness of breath. After taking the antacid several times daily for a few weeks, my shortness of breath abated and has not recurred. JG:  A 74-year-old man who, on January 5, 2022, complained of a new, pervasive feeling of shortness of breath for several weeks. The shortness of breath gets worse when he lies down, improves when he walks or becomes physically active, causes him to take in frequent deep sighs, and makes him feel anxious and panicked. He had normal vital signs, no tachypnea, and no cardiopulmonary or gastrointestinal symptoms. His laboratory tests and his physical examination were normal, but he had gained ten pounds to a weight of 223 lbs. during Christmas. Based on my long-term familiarity with this disorder, I attributed his subjective dyspnea to silent esophagitis secondary to silent gastroesophageal reflux. I reassured him because he had suffered from chronic anxiety-panic and had been on treatment with Buspirone for several years. After educating him, I gave him a therapeutic trial of liquid Maalox, liquid Gaviscon, Omeprazole 20 mg twice daily, and acid reflux precautions. He returned nine weeks later and reported that his subjective dyspnea had resolved after six weeks of treatment and that he had stopped taking Maalox, Gaviscon, and Omeprazole. He also related that his chronic anxiety-panic that were rekindled by his dyspnea had also remitted. He returned five months, nine months, and one year later, and was still free of subjective dyspnea and anxiety-panic. JD:  A 74-year-old man who, on June 3, 2021, complained of a new feeling of shortness of breath for several weeks. The shortness of breath comes when he is sitting, especially after meals, and it gets worse when he lies down. He takes frequent deep sighs, but they fail to temper his shortness of breath. When he is active, doing construction work, his shortness of breath disappears. He had been on long-term Omeprazole 20 mg/day for chronic gastroesophageal reflux. His laboratory tests, vital signs, and physical examination were normal. He had no tachypnea, cough, heartburn, or other gastrointestinal symptoms, but he had gained about 10 pounds to a weight of 159.3 lbs. His chronic anxiety-panic had been under good control with Clonazepam and were unaffected by his shortness of breath. Based on my long-term familiarity with this disorder, I attributed his subjective dyspnea to silent esophagitis secondary to silent gastroesophageal reflux and increased his Omeprazole to 20 mg twice daily, added 45 cc of liquid Maalox PRN for shortness-of-breath episodes, and instructed him in reflux precautions. He returned after three weeks and reported that his shortness of breath is coming only after dinner and that he is taking his Omeprazole in the morning and at bedtime but without food. I educated him that Omeprazole works best when taken before food and asked him to take his Omeprazole before dinner and to eat a small breakfast before taking it in the morning. He returned nine months later and reported that his shortness of breath was under control, that he was still taking Omeprazole twice daily, and that he’s able to abort shortness-of-breath episodes with liquid Maalox. He returned a year later and reported that his shortness of breath has totally disappeared, that he continues to take Omeprazole 20 mg twice daily, and that his anxiety-panic are still well controlled with Clonazepam. He returned 18 months later and reported that his shortness of breath has been under perfect control for over a year with Omeprazole 20 mg twice daily, that it used to come daily, that it used to frighten him, and that he is still treating occasional heartburn episodes, which come without dyspnea. He returned 27 months later and reported that his shortness of breath and gastroesophageal reflux were in total remission. Discussion Since my personal experience in 1969, I had treated several patients with esophageal pseudo-dyspnea and posted my observations on my medical blog on 10/15/2012 under the title False Shortness of Breath (Pseudodyspnea) . Last year, I shut down my web, but that same medical blog article was republished by The Monthly  magazine, Issue 125, December 2012. Understanding the vagal nerve’s ramifications is key to understanding esophageal pseudo-dyspnea. The vagus nerve (cranial nerve X) has four medullary nuclei: two nuclei (Nucleus of the Solitary Tract and Spinal Nucleus of the Trigeminal nerve) receive afferent input from the gastrointestinal, cardiac, pulmonary, and pharyngo-laryngeal systems. Two nuclei (Dorsal Motor Nucleus and Nucleus Ambiguus) send efferent output to modulate these four systems. The esophageal and the pulmonary vagal plexuses, which send afferent input to the Nucleus of the Solitary Tract, sense chemicals, inflammation, pressure, pain, stretch, temperature, and osmotic pressure. The Nucleus of the Solitary Tract transmits the received sensory information to multiple brain regions for interpretation. The vagal nerve efferent output from the Dorsal Motor Nucleus and Nucleus Ambiguus regulate respiration, feeding, heart rate, blood pressure, vascular resistance, and airway diameter. Chemical and inflammatory information from the lower esophagus is transmitted by the esophageal plexus, along afferent vagal fibers, to the Nucleus of the Solitary Tract—the same nucleus that also receives afferent fibers from the pulmonary plexus. This nucleus may provide a hub for the esophageal-pulmonary connection. It is conceivable that when the Nucleus of the Solitary Tract transmits the received information from the lower esophagus and from the lungs to multiple brain regions, the brain may misinterpret the information as dyspnea, which can trigger deep sighing. This referred esophageal-pulmonary feeling of shortness of breath is reminiscent of the referred left-arm pain of angina pectoris and the referred right-shoulder pain of gallbladder disease. Experimentally, bronchoconstriction and cough can be induced by acid infusion into the distal esophagus—via a vagally mediated reflex—which is another manifestation of the esophageal-pulmonary connection. Moreover, adverse effects of therapeutic vagal nerve stimulation include dyspnea in 8%, cough in 8%, and an increase in apnea/hypopnea episodes in patients who already have obstructive sleep apnea. Lower esophageal sphincter tone is regulated by the Dorsal Motor Nucleus of the vagus nerve. Transient relaxations of the lower esophageal sphincter are responsible for 63–74% of acid reflux episodes. Chronic cough can be a manifestation of gastroesophageal reflux without aspiration, and a therapeutic trial of acid suppression by proton pump inhibitors can confirm that diagnosis. In asthmatics, gastroesophageal reflux without aspiration can trigger asthma attacks that result from increased vagal tone and heightened bronchial reactivity. Episodic dyspnea that does not interfere with daily activities also occurs in 60–70% of healthy pregnancies and is more pronounced during the first trimester than the third. The mechanism of the episodic dyspnea of pregnancy is not known and no therapy has yet been advanced. Perhaps a therapeutic trial with liquid antacids may provide a diagnosis and a treatment. On palliative-care floors, agonizing dyspnea is treated with oxygen, morphine, and benzodiazepines. Since acid reflux is common in terminally ill, recumbent patients who are on medications that relax the lower esophageal sphincter, such as morphine, a therapeutic trial with liquid antacid may provide additional relief. The five clinical features of esophageal pseudo-dyspnea, as exemplified by these three case reports, are: The perceived feeling of shortness of breath is prolonged (spanning several weeks), is accompanied by frequent deep sighs, and is not accompanied by hyperventilation, tachypnea, cough, or heartburn. The perceived shortness of breath does not limit physical activity and does not worsen with exercise. The perceived shortness of breath resolves with intense anti-acid therapy and reflux precautions. The diagnosis of esophageal pseudo-dyspnea is clinical and is confirmed by response to intensive anti-acid therapy and reflux precautions. There are no reliable diagnostic tests; upper endoscopy reveals a low prevalence of esophagitis. Moreover, the absence of gastrointestinal symptoms renders the request for endoscopy unjustifiable. Preexisting anxiety-panic can be rekindled by esophageal pseudo-dyspnea and remit when the dyspnea resolves. Dyspnea fear is major among those with asthma, COPD, anxiety, panic, and phobias, but is less intense among normal subjects.² Conclusion Esophageal pseudo-dyspnea is common and causes apprehension, suffering, and expense, as judged by the number of calls I continue to receive, the thousands of hits my blog article⁵,⁶ has received, and the pseudo-dyspnea internet chatter that is still ongoing.¹⁴The afferent vagal fibers of the esophageal plexus have a much higher sensitivity for reflux esophagitis than endoscopes.¹¹ Wasting effort and expense on low-yield investigations is counterproductive. The best diagnostic test is still a therapeutic trial with intense acid suppression and reflux precautions. Conflict of Interest Statement The main author Dr. Saadah has not reported any conflict of interest. References Gruber C, Lehmann C, Weiss C, Niggemann B. Somatoform respiratory disorders in children and adolescents—Proposals for a practical approach to definition and classification. Pediatr Pulmonol . 2012;47:199–205. Carr RE, Lehrer PM, Hochron SM. Panic symptoms in asthma and panic disorder: A preliminary test of the dyspnea-fear theory. Behav Res Ther . 1992;30:251–261. Kara MZ, Basaran AE. Psychological profiles, quality of life, and parental attitudes in children with sighing dyspnea. Clin Child Psychol Psychiatry . 2022;27:769–781. Saadah H. Letter to the editor. Oklahoma County Medical Society Bulletin . 2013;September/October. Saadah H. False Shortness of Breath (Pseudodyspnea). [Internet]. Available from: http://hannasaadah.com/blog/medical/false-shortness-of-breath-pseudo-dyspnea-december-12/ Saadah H. False Shortness of Breath . The Monthly Magazine  [Beirut, Lebanon]. Issue 125, December 2012. (Electronic copy available upon request: hannasaadah@hotmail.com ). Yuan H, Silberstein SD. Vagus nerve and vagus nerve stimulation, a comprehensive review: Part I. Headache . 2016;56:71–78. Schachter SC. Vagus nerve stimulation therapy for the treatment of epilepsy. UpToDate . 2022. Harding SM. Gastroesophageal reflux, asthma, and mechanisms of interaction. Am J Med . 2001;111(8A):8S–12S. Irwin RS, Madison JM, Fraire AE. The cough reflex and its relation to gastroesophageal reflux. Am J Med . 2000;108(4A):73S–78S. Gurski RR, Da Rosa AR, Do Valle E, De Borra MA, Valiati AA. Extraesophageal manifestations of gastroesophageal reflux disease. J Bras Pneumol . 2006;32(2):150–160. Kahrilas PJ. Complications of gastroesophageal reflux in adults. UpToDate . 2022. Goland S, et al. Shortness of breath during pregnancy. Clin Cardiol . 2015;38:598–603. [Video link on pseudo-dyspnea]. Available from: https://youtu.be/k9Of97zpyuA

Hanna Saadah, MD,   FACP — Professor Emeritus of Internal Medicine, specializing in Infectious Diseases and Geriatrics I learned about the Therapeutic Potential Receptors  in the throat in one of our Geriatrics conferences. Taking a teaspoon of Yellow Home Mustard and not washing it off with water inhibits muscle tone and suppresses cramps. An 85-year-old veteran came to my clinic, accompanied by his son, complaining of nocturnal leg cramps that often wake him up from sleep. I asked him to swallow one teaspoon of Yellow Home Mustard to abort cramps. I also asked him to try one teaspoon of Yellow Home Mustard daily at bedtime to prevent nocturnal leg cramps. His son expressed skepticism, affirming that his father had tried many medications with no results. When the veteran and his son returned for follow-up in one month, the veteran expressed with astonishment that taking one teaspoon of yellow mustard did abort his cramps. When he started taking one teaspoon daily at bedtime, his nocturnal leg cramps stopped waking him up from sleep. The veteran’s son added that, like his father, he also suffered from nocturnal leg cramps. When he realized that the Yellow Home Mustard helped his father’s cramps, he began using it. His cramps did respond to Yellow Home Mustard, and taking a teaspoon daily at bedtime has stopped his nocturnal leg cramps. I have followed the veteran and his son for a year now, and they are still cramp-free. The neurological mechanisms are speculative and not well understood. Yellow Home Mustard, hypothesized to be working via the Therapeutic Potential Receptors in the throat, might suppress neuronal muscle tone stimulation, might enhance neuronal muscle tone inhibition, or might do both. Clinical experience does show that Yellow Home Mustard aborts and prevents nocturnal muscle cramps and has no serious adverse effects. A clinical therapeutic trial is indicated in nocturnal cramp sufferers.

Dr. Qaisar J. Qayyum Chief Editor, Noor Journal of Complementary and Contemporary Medicine, Clinical Assistant Professor, Oklahoma, USA.   Email :   chiefeditor@njccm.org Introduction: Despite rapid advances in diagnostics, therapeutics, and digital technologies, modern healthcare systems remain burdened by rising costs, escalating rates of chronic disease, and growing patient dissatisfaction. At the same time, the limitations of industry-funded research, often misaligned with real-world clinical outcomes, have become increasingly apparent. Many patients find that their lived experience does not match the optimistic claims of clinical trials, prompting a critical question: Is there anything else? For many, the answer is unclear, or simply not available, within conventional models. Biomedicine offers unmatched strengths in acute and emergency care. But when symptoms are vague, multifactorial, or chronic, the system’s answers often fall short. A Complementary and Integrative Medicine (CAIM) department offers a clinical philosophy centered on the whole person, not just the disease. It emphasizes therapeutic alliance, functional recovery, and pluralism in therapeutic tools. Yet in most hospital systems, complementary care remains fragmented, optional, or altogether absent. Patients are often left to self-navigate, self-diagnose, and self-medicate, frequently without clinical oversight. This can lead to adverse outcomes, including the misattribution of side effects to conventional medicine, when in fact they may stem from unregulated or inappropriate use of complementary therapies. When physicians lack familiarity with CAIM, or hold biased views against it, patients are left with little recourse but to act as their own healers. This exposes them to unnecessary risks and undermines coordinated care. This paper proposes an institutional framework for a Department of Complementary and Integrative Medicine : a real-world, physician-led, ethically governed structure to formally support complementary care wherever it is warranted, requested, or necessary. Reclaiming Health Sovereignty: CAIM as a Strategic Policy Blueprint We are living through a historic reckoning with federal health agencies and biomedical orthodoxy. Trust in centralized institutions is collapsing, not just among the public, but within scientific and clinical circles. People are asking hard questions: Have pharma-driven models overreached? Why are chronic disease, mental illness, and therapeutic fatigue still rising despite record spending? Where is the innovation patients actually want? In this vacuum, new models are gaining ground, and CAIM is one of them. But this isn’t just about herbs and acupuncture. A CAIM department is a blueprint for health sovereignty. It gives hospitals and governments the power to reclaim clinical authority from over-centralized, pharma-dependent systems and to reintroduce trusted, culturally grounded, patient-preferred therapies, under rigorous, physician-led governance. This framework aligns with the current political moment: decentralization, transparency, and personal choice. It resonates with lawmakers and reformers who no longer trust top-down medical gatekeeping and want solutions that reflect their values, not corporate scripts. This is not fringe. It’s strategic. It’s scalable. It’s popular. For legislators, health boards, and national agencies ready to take control of the healthcare narrative, this proposal is not merely necessary, it is long overdue. It delivers a ready-made, legally defensible model to build safer, pluralistic, and more accountable systems of care, without waiting for permission from institutions the public no longer believes in. Why CAIM Is No Longer Optional: A Clinical and Institutional Imperative The expansion of CAIM is not a hopeful experiment, it is a pragmatic response to systemic gaps in modern healthcare. Chronic disease, therapeutic fatigue, mental health strain, and cultural mismatch are driving patients toward complementary approaches, with or without clinical guidance. Ignoring this shift doesn’t preserve safety, it forfeits leadership. Hospitals, health systems, and governments that integrate CAIM under structured, physician-led governance aren’t taking risks, they’re managing them. They’re regaining control over a rapidly growing parallel industry, improving patient satisfaction, and rebuilding institutional trust in a landscape marked by disillusionment and demand for agency. The Clinical Rationale for Integration: Chronic pain, autoimmune complaints, mental health conditions, and medically unexplained symptoms continue to affect a growing proportion of adults. Published survey data show that many individuals seek complementary approaches specifically for these conditions, often after conventional treatments have proven insufficient or unsatisfactory [1]. CAIM offers alternatives or adjuncts to these paths by focusing on body–mind–spirit integration and functional resilience. The World Health Organization’s Global Report on Traditional and Complementary Medicine (2019), which reflects input from 179 member states, provides one of the most comprehensive global overviews of traditional, complementary, and integrative health practices. The report underscores the need for institutional integration, regulatory clarity, and evidence-based validation of these modalities within national health systems [2]. Current estimates indicate that between 30–50% of adults in high-income countries have used some form of complementary or alternative care [3,4]. This reflects not only cultural trends but also a growing unmet need within mainstream healthcare. The U.S. Veterans Health Administration, recognizing this, has implemented a multicenter Whole Health  initiative across its medical centers. According to one evaluation, 26% of veterans with chronic pain used complementary and integrative health (CIH) therapies. While many of these services were initially accessed in the community, an increasing proportion are now being delivered directly within VA facilities, due to the hiring of CIH providers at pilot sites [5]. Major centers like the Mayo Clinic and Memorial Sloan Kettering have already established dedicated integrative medicine departments embedded within their hospital systems [6,7]. Peer-reviewed data support this shift. Studies show that CAIM is associated with improved symptom control, decreased opioid reliance, fewer hospital days, and better patient satisfaction [8,9]. Improved physician satisfaction and reductions in burnout are also reported in environments where clinicians have access to a broader range of therapeutic modalities [10]. Department Structure and Leadership: The proposed department is led by a medical doctor (MD or DO) with both clinical and academic interest in integrative modalities. The lead physician provides oversight for clinical care, regulatory compliance, and patient assignment to appropriate CAIM modalities. Complementary specialists, such as homeopaths, herbalists, acupuncturists, and practitioners of Ayurveda, Hikmat/Unani, and Traditional Chinese Medicine (TCM), function as Independent Licensed Professionals (ILPs)  within the department. ILPs function  under shared clinical governance within their licensure scope and do not independently manage primary diagnosis or prescription unless legally authorized.  Each contributes modality-specific recommendations under the shared clinical governance of the lead physician. Importantly, this structure is collaborative, not hierarchical. It preserves each discipline’s autonomy while maintaining biomedical safety standards.     Patient Selection and Referral Criteria: The S.C.O.P.E. Model Referrals to the CAIM department follow clearly defined clinical logic. The S.C.O.P.E. model outlines five eligible scenarios: S – Symptoms  are either mild or early-stage, and the patient is not yet ready to begin conventional therapy; or they are severe and unresponsive to standard treatment. C – Conventional care  has been exhausted, yet the disease continues to progress despite adherence to prescribed treatment, or the patient wishes to supplement ongoing care with CAIM. O – Observation phase , in which diagnosis remains unclear and complementary therapy is only used when deemed medically appropriate and with clear documentation that complementary care does not delay or interfere with critical diagnostics and urgent treatments. P – Patient preference , informed and documented, to pursue CAIM despite the availability of conventional options. E – End-stage disease , with limited options remaining and a desire for comfort, dignity, or spiritual alignment through supportive CAIM approaches. These scenarios represent familiar clinical challenges where patients may be open to complementary options, particularly when conventional treatments are limited or ineffective. Documenting such cases brings structure, safeguards, and clinical accountability to the referral process. This proposed model offers a practical, testable framework  for patient selection that can be piloted across diverse clinical settings, refined through implementation experience, and potentially standardized for broader institutional use. Daily Workflow and Clinical Operations: Each clinical day begins with a structured morning huddle involving the lead MD/DO, nurse case manager, and CAIM clinicians. They review the day’s scheduled patients, these are not walk-ins, but referred cases with documented histories and clear therapeutic goals. The referring physician has already discussed the rationale with the patient and formally requested evaluation, ensuring the system functions like any other subspecialty consult service. Treatment suggestions are proposed collaboratively, for example, individualized homeopathy for long COVID-related fatigue, acupuncture for diabetic neuropathy, or herbal tonics for digestive dysregulation. The lead physician evaluates each proposal for safety, supporting evidence, and compatibility with the patient’s ongoing care and the scope of the relevant CAIM discipline. Approved interventions are integrated into the electronic medical record (EMR) and monitored through structured follow-up. Importantly, care remains fully integrated, not fragmented. Patients are never simply handed off; they stay anchored within the formal medical system, ensuring they receive proper guidance and are not left to navigate unregulated or potentially unsafe therapies on their own. This structure protects patients from misinformation and risk, which often emerge when conventional care offers no support for those exploring complementary options. All complementary care plans and progress notes are documented in medically appropriate formats within the shared EMR. Standardized, legally binding consent forms, risk disclosures, and follow-up metrics ensure accountability and continuity. Ethical and Clinical Boundaries: Ethics and patient safety are foundational to the operation of a CAIM department. All interventions must adhere to clinical protocols designed to ensure that therapies are not only appropriate but responsibly applied within the medical framework of care. 1. Explicit Informed Consent: Patients are required to provide written, culturally sensitive, and medically appropriate informed consent before initiating any complementary intervention. Consent forms detail the modality offered, its rationale, anticipated benefits, potential side effects, and alternative options, including choosing no intervention. Practitioners are trained to avoid coercion or exaggerated claims and instead foster informed, patient-led decision-making. 2. Drug-Herb and Modality Interaction Review: Each CAIM provider, while independently licensed and responsible for their treatment plans, is expected to proactively consult the lead physician, and when appropriate, a clinical pharmacist, regarding any potential interactions with the patient’s current medications. Given that some side effects may be unknown, and many complementary therapies have not been studied alongside conventional drugs, treatment decisions are guided by traditional use, clinical experience, and expert consensus, in alignment with current pharmacological knowledge and institutional medication safety guidelines . In cases of uncertainty, collaborative judgment and close monitoring help ensure patient safety. 3. Adjustments for Comorbidities and Contraindications: Each intervention is carefully tailored to the patient’s broader clinical picture. For example, individuals with renal impairment may require exclusion of nephrotoxic herbs, while those with bleeding disorders may not be suitable candidates for acupuncture unless the risk is demonstrably low or clearance is obtained from their hematologist. All such decisions are made with appropriate documentation and, when needed, interdisciplinary input to ensure patient safety.   4. Transparency and Communication: Therapies are presented with honesty and respect for both traditional wisdom and scientific inquiry. While curative outcomes are not guaranteed and remain subject to further validation, the historical and experiential basis of many treatments is acknowledged. Homeopathic and herbal therapies are offered with full disclosure of ingredients and intent, and may be used as adjuncts, or, when chosen by the patient with informed consent, as primary therapies only when the patient is fully informed of conventional options, prognosis, and risks, and such choice is documented and co-signed by the lead physician. The emphasis remains on open dialogue, shared decision-making, and clarity of therapeutic goals. 5. Practitioner Boundaries and Scope of Practice: Complementary practitioners operate within the limits of their professional training and licensure, contributing their expertise as part of a collaborative care team. They do not independently advise on starting, stopping, or altering conventional medical treatments. If such questions arise during a consultation, they are brought to the attention of the lead physician and documented appropriately in the medical record to ensure coordinated, safe care. 6. Documentation and Monitoring: Complementary interventions are recorded in the electronic medical record using simple, standardized templates that capture key details such as rationale, formulation, dosage (when applicable), intended goals, and any observed effects. Documentation supports continuity of care and shared understanding across the clinical team. As the department grows, periodic case discussions or informal peer reviews may be introduced to help maintain quality and support reflective practice. 7. Innovation and Institutional Contribution: Practitioners are encouraged to draw on traditional knowledge, clinical experience, and individual patient needs to propose novel therapeutic formulations. When deemed potentially beneficial, such contributions may be submitted to the institutional pharmacy for review, with any clinical use occurring under physician oversight. This process supports innovation while ensuring that all therapies align with standards of transparency, safety, and collaborative accountability. Any novel formulation will be reviewed under institutional CAIM protocols, and not distributed outside clinical context. Modest commercial activity that supports the viability of practitioner-led innovations should not be excluded under overly broad interpretations of conflict of interest. When carried out transparently, without coercion, exaggerated claims, or undue influence, and with full disclosure to patients and the institution, such contributions can strengthen both clinical care and academic growth. Their ethical grounding lies in their transparency, patient-centered intent, and alignment with the department’s mission: advancing integrative, accountable care and fostering the development of new therapeutic formulations and inventions. Dismissing the expertise of department members in the name of rigid conflict-of-interest policies would not only be a disservice, it would risk obstructing the very innovation the department was created to support. The Economic and Clinical Imperative: The establishment of a CAIM department is not a luxury, it is a timely, evidence-supported strategy for clinical and financial sustainability. As conventional medicine grapples with rising costs, therapeutic plateaus, and growing public disillusionment, CAIM offers measurable, system-level solutions. A large multi-center cohort study found that patients receiving integrative therapies experienced a 43% reduction in hospital admissions  and over 58% fewer inpatient days than matched controls [8]. These gains are not theoretical, they translate into shorter stays, increased bed availability, lower per-patient costs, and improved care flow. The most notable benefits were seen in areas like chronic pain, anxiety, and stress-related disorders , where conventional approaches often stall [9]. Meanwhile, 30–50% of adults  in high-income countries already use some form of complementary or alternative care, frequently outside formal clinical settings and without their physicians’ knowledge [3,4]. This disconnect fuels the rise of a parallel, unregulated, and potentially unsafe industry . When hospitals ignore this demand, patients turn to informal markets where misinformation spreads, safety is compromised, and continuity of care is lost. The result is erosion of trust, not in pharmaceutical companies, but in hospital. CAIM departments not only close this gap, they meet patients where they already are. Hospitals that have embraced integrative models report higher patient satisfaction , stronger community loyalty , and a return to whole-person, preventive, and culturally aligned care  [6]. Clinicians also benefit. CAIM environments are consistently associated with lower burnout , richer patient relationships , and broader therapeutic flexibility , renewing purpose and improving retention [10]. Integrating CAIM is more than a clinical upgrade, it is a marketable signal of institutional leadership in an era of shifting expectations. The Political and Strategic Wake-Up Call: If the clinical case is compelling, the strategic warning is urgent. On June 9, 2025 , U.S. Health Secretary Robert F. Kennedy Jr. , a prominent vaccine skeptic, fired all 17 members  of the CDC’s Advisory Committee on Immunization Practices (ACIP). This was not an isolated decision, it was the latest tremor in a broader political earthquake. Under a second Trump administration , scientific consensus is being dismantled, public health agencies are being hollowed out, and decades of biomedical orthodoxy are being rewritten by executive fiat. In this volatile landscape, hospitals, not pharmaceutical companies, are on the front line . When trust in science falters, it is the local health systems and clinicians that patients confront with their confusion, fear, and frustration. If institutions remain tethered to outdated, pharma-centric models of care, they may find themselves scapegoated for a crisis they didn’t create, but failed to prepare for. This is where the Kodak analogy  becomes painfully real. Kodak once owned the film photography market. It even invented digital imaging. But it failed to act, not due to ignorance, but out of fear of disrupting its own status quo. Hospitals today face the same crossroads. Dismissing CAIM as fringe or irrelevant, while millions of patients vote with their feet, is not caution. It’s capitulation. The decision not to diversify is not ethically neutral. It is a strategic miscalculation with existential consequences. Loyalty to the pharmaceutical-industrial model will not protect hospitals from political disruption, public backlash, or market abandonment. But there is still time to lead. A thoughtfully implemented CAIM department is not just good medicine, it is future-proofing. It tells the public: We are listening. We are evolving. We are not afraid to serve with both science and wisdom.  It tells staff: We trust your clinical judgment and are restoring depth to the healing mission. Hospitals now face a binary choice: Path Outcome Resist Relevance fades, trust collapses, patient volumes shrink—and the institution becomes the next Kodak . Adapt Reclaim leadership, meet real-world patient needs, and secure a resilient, future-aligned care model. This is not a passing trend, it is a turning point: Hospitals that hesitate now may lose their competitive edge and find they no longer have the opportunity to catch up later. Despite rapid advances in diagnostics, therapeutics, and digital technologies, modern healthcare systems remain burdened by rising costs, escalating rates of chronic disease, and growing patient dissatisfaction . This proposal aligns with key health policy priorities across major global blocs. In ASEAN , it supports the Vision 2025 agenda to integrate traditional and complementary medicine into universal health coverage frameworks (14). Within the African Union , it echoes the African Traditional Medicine Strategy , which promotes the institutionalization and regulation of indigenous therapies (15). Across these regions, a department of CAIM offers a sovereign, scalable model, empowering nations to strengthen primary care, reduce pharmaceutical dependence, and align medical practice with cultural values makes healthcare more accessible and responsive to patient demand. National Relevance and African Implementation Pathways: Across Africa, governments are working to deliver healthcare that is accessible, culturally resonant, and financially sustainable, while confronting rising costs and persistent rural health disparities. A Department of CAIM offers a practical solution already aligned with continental priorities. The African Union’s Traditional Medicine Strategy 2021–2030  calls for the formal institutionalization, regulation, and research of traditional and complementary medicine across member states. This CAIM framework provides an operational vehicle to fulfill that strategy, within hospitals, medical schools, and regional health systems. It builds on indigenous knowledge, strengthens trust in public care, and reduces overdependence on pharmaceutical imports. For countries like Uganda, Ghana, Nigeria, Kenya, and others with longstanding traditional health systems, CAIM departments allow ministries to harness existing practices  while raising standards through physician-led governance, safety protocols, and integration into national electronic records. Rather than creating parallel systems, this model embeds trusted therapies into formal care delivery, improving access, continuity, and accountability. This approach also supports local economies. By formalizing the use of African herbal medicine and supporting indigenous healer networks through training and oversight, ministries can stimulate national production, reduce import burdens, and promote intellectual property development  tied to regional biodiversity. In an era where African health sovereignty and self-reliance are becoming both a political and economic imperative, the CAIM department is not only a clinical tool, it is a strategic asset. Ministers seeking scalable, culturally appropriate, and internationally defensible health reform will find in this proposal a credible and ready-to-launch model grounded in African realities. Building on Prior Models: What Makes This Proposal Distinct: The integration of CAIM into hospital-based care has been attempted across several respected institutional and academic settings. Programs at centers such as Memorial Sloan Kettering, Mayo Clinic, and the Veterans Health Administration have demonstrated that safe, patient-centered integrative services can be meaningfully embedded within conventional healthcare systems. In parallel, research by organizations like the RAND Corporation [11] and academic centers including UNC Chapel Hill [12] has helped clarify the structural, regulatory, and epistemological barriers that continue to challenge widespread adoption. This proposal builds upon those foundational efforts while advancing a more practical, replicable model , grounded in clinical pragmatism and institutional design . Unlike earlier initiatives that often remain boutique in scale or reliant on temporary grants, the framework presented here prioritizes operational feasibility , clinical governance , and financial sustainability . It is built not merely to coexist alongside the biomedical enterprise, but to function as a full-fledged department, complete with credentialed roles, integrated documentation, safety protocols, referral logic, and outcome tracking. Several features distinguish this model from prior attempts: Physician-led, co-managed structure:  Positions CAIM within the formal medical hierarchy to ensure patient safety, institutional trust, and meaningful collaboration, while preserving appropriate autonomy for licensed complementary practitioners. Structured referral logic (S.C.O.P.E. model):  Provides clear criteria for when and why referrals are made, replacing ad-hoc or anecdotal practices with clinical reasoning and accountability. EMR harmonization and clinical documentation:  Applies the same standards of documentation, coding, and quality assurance to CAIM services as to mainstream medical departments, ensuring parity and continuity of care. Culturally inclusive therapeutic scope:  Accommodates globally recognized modalities like acupuncture and Chinese medicine, as well as regionally relevant systems such as Ayurveda, Hikmat, and Unani, supporting both diversity and relevance. This framework is offered not as a fixed or prescriptive model, but as a living clinical blueprint , informed by real-world successes, mindful of persistent challenges, and responsive to the evolving expectations of patients, clinicians, and healthcare systems. Conclusion and Next Steps: This proposal outlines a clinically grounded, ethically structured framework for establishing a department of CAIM within a modern healthcare institution. By integrating evidence-informed complementary modalities into the biomedical setting, it addresses longstanding gaps in patient care, particularly for conditions that remain underserved or inadequately managed by conventional approaches alone. The model is designed to support safe, accountable, and culturally responsive care within a structure that is fully compatible with hospital systems. This framework offers a replicable foundation for institutions seeking to implement whole-person, interdisciplinary care in a way that is both operationally viable and professionally credible. Part Two  of this article will focus on the operational implementation of the department within a real-world institutional context. It will detail infrastructure requirements, team-based clinical workflows, EMR integration strategies, governance structures, reimbursement pathways, and systems for tracking clinical outcomes. Drawing on lessons from established integrative programs across North America and Europe, it will include visual schematics and practical guidance to support translation of this model from concept to clinic. In an era marked by rising rates of chronic disease, therapeutic burnout, and growing demand for culturally competent care, this proposal offers a timely and actionable path forward. It is designed to be medically sound, ethically governed, and institutionally replicable, positioning hospitals to lead, rather than lag, in the future of integrative health. Acknowledgment: This article was written with AI assistance. All claims are supported by credible, peer-reviewed references, which were validated for accuracy and authenticity. The AI synthesized information were reviewed by authors, ensuring scientific integrity throughout. In the event of any inadvertent errors, the responsibility lies with the AI/authors, and corrections will be made promptly upon identification. I would like to express my sincere gratitude to Dr Tahira Khalid, for her thoughtful review and invaluable feedback. Her expertise and guidance have played a pivotal role in refining and enhancing this article.   Conflict of Interest Statement: The author is the developer of a herbal formula and the owner of Dr. Q Formula/Insulinn LLC. However, this affiliation has not influenced the content, analysis, or conclusions of this article   Author’s Note on Scope and Intent: This proposal does not advocate the replacement of evidence-based conventional care with CAIM modalities. All complementary interventions are intended to supplement, not supplant, standard clinical practice, and are implemented within a physician-governed, ethically reviewed, and fully documented medical framework. References Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the Use of Complementary Health Approaches Among Adults: United States, 2002–2012.  Natl Health Stat Report. 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573565/ World Health Organization. Global Report on Traditional and Complementary Medicine 2019.  Geneva: WHO; 2019. https://www.who.int/publications/i/item/978924151536 Posadzki P, Watson LK, Ernst E. Prevalence of complementary and alternative medicine (CAM) use by the general population: A systematic review and update.  Clin Med (Lond). 2013;13(2):126–131. https://pubmed.ncbi.nlm.nih.gov/23681857/ Frass M, Strassl RP, Friehs H, Müllner M, Kundi M, Kaye AD. Use and acceptance of complementary and alternative medicine among the general population and medical personnel: A systematic review.  J Integr Med. 2012;10(3):208–219. https://pubmed.ncbi.nlm.nih.gov/22438782/ Bokhour BG, Hyde J, Charns MP, Kligler B. Whole Health System of Care Evaluation: A Progress Report. Glob Adv Health Med. 2020. https://www.va.gov/WHOLEHEALTH/docs/EPCC_WHSevaluation_FinalReport_508.pdf Mayo Clinic. Integrative Medicine and Health – Overview.   https://www.mayoclinic.org/departments-centers/integrative-medicine-health/sections/overview/ovc-20464567 Memorial Sloan Kettering Cancer Center. Integrative Medicine Service.   https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine Chao MT, Tippens KM, Connelly E. Utilization of Group and Individual Acupuncture Services in an Integrative Medicine Program.  J Altern Complement Med. 2019;25(S1):S70–S77. https://pubmed.ncbi.nlm.nih.gov/25749600/ Herman PM, Poindexter BL, Witt CM, Eisenberg DM. Are Complementary Therapies and Integrative Care Cost-Effective? A Systematic Review of Economic Evaluations.  BMJ Open. 2012;2(5):e001046. https://pubmed.ncbi.nlm.nih.gov/22945962/ Dossett ML, Cohen M, Kligler B, Wayne PM. Integrative Medicine Program Enhances Patient and Clinician Experience and Well-Being at Academic Health Centers.  Glob Adv Health Med. 2018;7:2164956118818043. https://pubmed.ncbi.nlm.nih.gov/30428106/ RAND Corporation. Hospital-Based Integrative Medicine: A Case Study.  Santa Monica, CA: RAND Health; 2006. https://www.rand.org/pubs/monographs/MG591.html University of North Carolina. Integrating CAM into Conventional Practice: Barriers and Best Practices.  UNC School of Medicine, Department of Physical Medicine & Rehabilitation. 2018. https://www.med.unc.edu/phyrehab/pim/wp-content/uploads/sites/615/2018/03/Integrating.pdf StartupTalky. Kodak Case Study – How They Went Bankrupt.   https://startuptalky.com/kodak-bankruptcy-case-study/ ASEAN Secretariat. ASEAN Post-2015 Health Development Agenda (2021–2025).  Jakarta: ASEAN; 2024. Available from: https://asean.org/wp-content/uploads/2024/04/E-Publication-ASEAN-Post-2015-Health-Development-Agenda-for-2021-2025-1.pdf African Union Commission. Africa Health Strategy 2016–2030.  Addis Ababa: African Union; 2016. Available from: https://au.int/sites/default/files/pages/32895-file-africa_health_strategy.pdf

Dr. Qaisar J. Qayyum Chief Editor, Noor Journal of Complementary and Contemporary Medicine, Clinical Assistant Professor, Oklahoma, USA. Email :   chiefeditor@njccm.org Abstract Evidence-Based Medicine (EBM) was established to enhance clinical decision-making by anchoring it in methodologically rigorous research. However, its foundational tools—randomized controlled trials (RCTs), meta-analyses, and statistical inference, have come under increasing scrutiny. The critique lies not in the scientific principles themselves, but in the selective and often distorted ways these tools are applied, interpreted, and communicated. This multi-part article critically explores the structural biases, linguistic framing, and methodological manipulations that shape contemporary clinical literature. Through case studies on statin use, selective serotonin reuptake inhibitor (SSRI) efficacy, and anticoagulation strategies, it illustrates how modest benefits are overstated, adverse effects minimized, and marginal findings rhetorically elevated to therapeutic significance. In its concluding section, the article proposes a constructive epistemological model that redefines medical certainty as a dynamic interplay of statistical inference, clinical observation, and lived patient experience. This integrative framework seeks to restore the epistemic integrity of medical evidence while fostering renewed trust in its clinical application.   Introduction: The Crisis Behind “Show Me the Study” “Show me the study” has become a common rhetorical weapon in medical and public discourse, used to affirm authority, silence skepticism, and end debate with the appearance of objectivity. But beneath this demand lies a deeper, often unexamined question: What qualifies as a valid study? Who defines its credibility, and by what assumptions is it judged?            Evidence-Based Medicine (EBM)  was originally designed to elevate clinical care by grounding decisions in rigorous, empirical data. It aimed to replace opinion and anecdote with reproducible results, measurable endpoints, and systematic inquiry. Yet in practice, that noble vision has drifted. As this article will show, EBM today is increasingly shaped by statistical distortions, commercial incentives, and methodological shortcuts that mask weak results behind the illusion of scientific authority.          Algorithms Over Judgment: The Rise of “Cookbook Medicine” While Evidence-Based Medicine (EBM) was conceived to elevate clinical care through rigorous data, its application in practice has increasingly collapsed nuanced decision-making into rigid, algorithmic routines. Clinical calculators and decision trees, initially developed to assist with complex decisions, are now often treated as mandates rather than guides. This shift has given rise to what critics call “cookbook medicine”: a mechanistic adherence to protocols based on population averages, with inadequate attention to the physician’s clinical expertise or the individual patient’s context and values. Consequently, interventions validated under idealized study conditions are frequently applied indiscriminately to patients who fall outside trial demographics, such as the elderly, those with multiple comorbidities, or individuals with distinct cultural or personal priorities. For example, rigid application of antihypertensive or anticoagulation guidelines, based solely on numerical thresholds, can result in overtreatment, complications, or disregard for quality-of-life considerations. EBM, when properly understood, was never intended to replace clinical judgment, but to inform  it. It rests on three pillars: the best available evidence, the clinician’s expertise, and the patient’s values and circumstances. Undermining any one of these, particularly the latter two—risks reducing medicine from a healing art to a protocol-driven enterprise, vulnerable to depersonalization and, ultimately, algorithmic automation. One of the most forceful critiques of modern Evidence-Based Medicine comes from Dr. John P.A. Ioannidis, the renowned epidemiologist and author of Why Most Published Research Findings Are False . In a 2016 editorial in The BMJ  (29), he warned that EBM has been “hijacked” by commercial interests, bureaucratic overreach, and conflicted guideline panels. What began as a scientific reform movement, he argues, now risks devolving into a system shaped more by marketing, convenience, and industry lobbying than by clinical relevance or scientific rigor. Loannidis contends that many published findings, though presented with statistical sophistication, are often more likely to be false than true, due to flexible trial designs, underpowered studies, and selective reporting. Guidelines, once a reflection of consensus, are increasingly distorted by conflicts of interest and institutional inertia. This critique echoes our central thesis: that EBM, stripped of clinical judgment and patient context, risks becoming a rigid, protocol-driven system where abstractions like hazard ratios or relative risk reductions dominate, while meaningful outcomes and patient values are marginalized. If this trend continues, evidence-based care may become numerically precise yet clinically hollow. Reclaiming its original spirit requires a renewed commitment to relevance, humility, and transparency. Consider, for example, initiating antihypertensive therapy solely because blood pressure exceeds 140/90 mmHg, or prescribing anticoagulation the moment a CHA₂DS₂-VASc score reaches 2. While seemingly evidence-based, such actions often bypass the very elements what matters most  to many patients, functional capacity, autonomy, and quality of life. These priorities are especially critical in outcomes research on multimorbidity and aging, which emphasize preserving independence and minimizing treatment burden over meeting arbitrary targets (26). Rather than empowering clinicians, these tools often displace judgment, turning medicine into checklist management. Numbers replace narratives. Protocols overshadow context. Figure 1: A Patient-Centered Vision for Evidence-Based Medicine. This figure presents a reoriented vision of EBM grounded in real-world relevance, patient priorities, clear communication of results, and the deliberate avoidance of unnecessary scientific-sounding jargon. The goal is evidence that informs, not obscures, clinical decision-making.   The GDMT Paradigm: From Science to Scorecard One of the most visible examples of this drift is the rise of GDMT— Guideline-Directed Medical Therapy , in quality dashboards, EMR templates, and hospital performance metrics. Though meant to ensure standardized care, GDMT often reduces nuanced medical reasoning to rote prescription of approved drugs. Physicians are assessed less on judgment than on whether specific medications were ordered, regardless of a patient’s frailty, comorbidities, or treatment preferences. The result is a flattening of individualized care, shaped more by regulatory incentives and pharmaceutical input than by patient-centered wisdom When Protocols Replace Patients: Ossification of Evidence-Based Medicine This shift exemplifies what some have called the “ossification” of Evidence-Based Medicine (EBM), in which the original balance between best evidence, clinical expertise, and patient preference is displaced by protocol compliance shaped more by population averages, regulatory demands, and industry influence than by individualized care. As a practicing clinician, I have observed, alongside many peers, that thoughtful, patient-centered decisions are too often marginalized in favor of institutional metrics. Greenhalgh et al. warn that EBM is in crisis not due to a lack of data, but because it has lost the very equilibrium that once made it valuable: the integration of science, judgment, and human priorities [30]. In this climate, medicine risks devolving into a bureaucratic routine, undermining clinical autonomy, eroding patient trust, and compromising the ethical foundations of care. A Mirror for a Broken System This pattern reflects a broader truth: like democracy, which thrives in principle but falters in execution, EBM must be judged not by its ideals but by its real-world outcomes. If it is to be reclaimed, EBM must return to its roots, rebalancing scientific rigor with narrative understanding, population evidence with individual meaning, and statistical significance with clinical significance. Figure 2:  Summary of the deviation of Evidence-Based Medicine from its original intent, highlighting statistical bias, rigid algorithms, and the erosion of patient-centered care. Case in Point: Antihypertensive Therapy in the Elderly Consider an 85-year-old patient with multiple comorbidities and a recent history of falls, presenting with a blood pressure of 145/85 mmHg. According to guideline thresholds, this patient qualifies for antihypertensive treatment. But blindly applying this cutoff may do more harm than good. A cohort study in JAMA Internal Medicine  found that older adults on antihypertensives, especially those with a prior fall injury, had a significantly higher rate of serious fall-related hospitalizations than non-users ( 1 ).   For this patient, the most meaningful outcome may not be tighter blood pressure control, but preserving balance, reducing medication burden, and maintaining independence . Reclaiming EBM: From Rhetoric to Relevance This article challenges the mythologized status of “the study” by exposing the structural, rhetorical, and philosophical distortions  embedded in much of today’s clinical evidence. The issue is not a lack of data, but rather how that data is produced, selected, framed, and disseminated, often in ways that obscure the very people it is meant to help. In the sections that follow, we examine how modern studies are structured to inflate marginal benefits, downplay harms, and transform weak findings into clinical doctrine . From framing bias and surrogate endpoints to semantic manipulation and exaggerated statistics, these patterns form a system that appears methodologically sound but is too often detached from clinical relevance and patient need . The goal is not to reject science, but to rescue it from misuse . To reclaim a model of evidence that reflects what matters most, not just what is easiest to measure.   Common Pitfalls in Clinical Trials The Mechanics of Bias: How Studies Are Built to Deceive Many of the problems in modern clinical literature stem not from isolated errors, but from design practices that, intentionally or not, produce overly favorable results . Before a single patient is enrolled, the architecture of a trial can be shaped to amplify benefits, suppress harms, and tilt outcomes toward a desired conclusion. While each design choice may seem minor in isolation, their cumulative effect constructs a narrative more favorable than the underlying data justifies. Behind the polished surface of randomized controlled trials (RCTs) and systematic reviews lies a landscape of methodological shortcuts , semantic distortions , and statistical manipulations . These tactics, while often unnoticed by casual readers, are well-documented and widespread. The result : publications that are mathematically correct, statistically significant, and peer-reviewed, but conceal crucial gaps in relevance, rigor, or reproducibility in real-world patient populations.   Structural and Methodological Distortions 1.    Poor Generalizability Narrow inclusion criteria and tightly controlled environments produce clean data that often fails to reflect real-world complexity. ( 2 ) 2.    Ethnic and Demographic Homogeneity Trials that enroll predominantly white, middle-class participants cannot reliably predict effects across diverse populations. ( 3 ) 3.    Skewed Sample Selection Inclusion and exclusion criteria are often manipulated to favor ideal patient profiles—excluding elderly, multimorbid, or medication-intolerant patients. ( 3 , 4 ) 4.    Washout/Run-in Periods Participants who experience early adverse effects during pre-randomization phases are often excluded from randomized controlled trials through washout or run-in procedures. While this strategy is sometimes methodologically can be justified, it can distort the reported safety profile of an intervention. For instance, statin trials report low rates of muscle pain, with one high-profile study claiming that over 90% of reported symptoms were not attributable to the drug itself [28]. In contrast, large-scale observational studies and patient surveys tell a different story. One real-world study found a 73.5% prevalence of muscle pain  among statin users (95% CI: 68.4–78.1%), with lower limb pain being the most common site [27]. This discrepancy highlights how selective trial enrollment can obscure adverse effects that are frequent and clinically relevant in routine practice [5] Figure 3. Discrepancy in Reported Statin-Associated Muscle Pain. This visual compares the incidence of muscle pain reported in randomized clinical trials (e.g., 4–10%, with over 90% deemed unrelated to statins) versus real-world observational data, where up to 73.5% of patients reported muscle-related symptoms. 5.    Confirmation Bias in Design. Many studies begin with an implicit belief in the intervention’s benefit, influencing design choices that favor positive outcomes. ( 6 ) 6.    Surrogate and Composite Endpoints Rather than measuring actual clinical improvements (e.g., survival), many trials rely on indirect proxies like lab values or imaging changes. These may not translate to meaningful patient benefit. ( 7 ) 7.    Multiple Endpoints and Data Mining Including numerous exploratory or secondary outcomes increases the odds of chance findings being presented as significant. ( 8 )    8.    Underpowered Sample Sizes Trials with small numbers may lack the statistical power to detect real effects—or may produce false positives due to random variation. ( 9 )     9.    Poor Reporting of Key Metrics Critical data such as Number Needed to Treat (NNT) or Number Needed to Harm (NNH) are missing in over 90% of trials, hindering interpretation. ( 10 ) 10. Relative Risk Reporting Without Absolute Context Relative changes are often highlighted, e.g., “42% reduction in coronary deaths”, without disclosing that the absolute difference was just 3.5%.  ( 11 ) 11. Mathematical Obfuscation Clear clinical metrics are replaced with statistical abstractions (e.g., hazard ratios, standardized effect sizes) that obscure clinical meaning. ( 12 ) 12. Low Thresholds for Success Modest improvements (e.g., 25–30% symptom reduction) may be labeled “recovery,” even when patients experience little meaningful benefit. ( 13 ) 13. 13. Placebo vs. Active Comparator Drugs are often tested against placebo rather than existing standard treatments, exaggerating perceived efficacy. ( 14 ) 14. Disconnect from Clinical Practice Randomization, while methodologically sound, often strips away the variability inherent in real-world medicine. ( 15 ) 15. Rhetorical Ambiguity and Framing Bias Strategic language, e.g., “clinically meaningful,” “consistently higher NNT”, and persuasive visuals can inflate impressions of efficacy. ( 16 ) 16. Publication Bias Negative or inconclusive results are far less likely to be published, distorting the perceived weight of evidence. ( 17 ) 17. Commercial Influence Industry-sponsored trials are significantly more likely to report favorable outcomes due to preferential design, analysis, and reporting practices.( 18 ) 18. Guideline Distortion Many treatment guidelines are shaped more by cost-efficiency, institutional priorities, or industry lobbying than by unbiased, patient-centered data. ( 19 ) 19. Weak Evidence as Clinical Doctrine As demonstrated by multiple examples throughout this article, marginal or biased data is often elevated into official protocols and performance metrics. This enshrinement restricts clinician autonomy, institutionalizes suboptimal practices, and ultimately risks compromising patient care These recurring patterns reveal that even when studies are labeled “randomized,” “controlled,” or “peer-reviewed,” they may rest on compromised ground. Recognizing these pitfalls is not cynicism, it is essential to reclaim medical science as a vehicle for truth , not just technique.   Framing Bias: When Numbers Speak Louder Than Truth A Closer Look at the Gold Standard One of the most pervasive tactics used to exaggerate clinical benefit is framing bias, the practice of reporting relative risk reduction (RRR) without simultaneously disclosing absolute risk reduction (ARR) or Number Needed to Treat (NNT). This selective framing inflates perceived efficacy and can mislead both clinicians and patients. Case in Point: Statins and the Illusion of Impact A widely cited case illustrating the limitations of relative risk framing involves the use of statins for secondary prevention of cardiovascular events. According to independently evaluated data from TheNNT.com (20), the absolute benefits  of statins over a five-year period are modest, while the risks remain clinically significant : 1 in 83 patients (1.2%)  will have their life saved 1 in 39 (2.5%) will avoid a non-fatal heart attack 1 in 125 (0.8%) will avoid a stroke 1 in 10 (10%) will experience muscle damage 1 in 50 (2%) will develop diabetes While these figures offer a numerical summary, how they are presented dramatically alters their perceived impact. In many public-facing materials, statins are promoted using relative risk reductions, with statements like: “This 42% reduction in the risk of coronary death accounts for the improvement in survival” in the Scandinavian Simvastatin Survival Study (4S). ( 21 ) Relative Risk Reduction vs. Absolute Benefit Let’s take a closer look at that 42% claim. In the 4S trial, there were 189 coronary deaths in the placebo group versus 111 in the simvastatin group. This yielded a relative risk  of 0.58, often publicized as a “42% reduction in coronary deaths.” Yet this figure masks the more relevant absolute risk reduction : a drop from 8.5% to 5.0%, or just 3.5%. This translates to a Number Needed to Treat (NNT) of 29 over six years, meaning 29 people would need to take the drug for that period to prevent one coronary death. This framing bias, emphasizing relative benefit, can make modest outcomes appear impressive, especially when serious harms like diabetes or muscle damage are also possible.                    Figure 4 .   Coronary death rates in the Scandinavian Simvastatin Survival Study (4S) over six years . While the relative risk reduction  was 42%, the absolute risk  dropped from 8.5% in the placebo group to 5.0% in the statin group, a difference of just 3.5% . When Visuals Deceive: The Power of Presentation As outlined by the Royal Australian College of General Practitioners,[ 22 ] a high-risk 65-year-old man who smokes and has hypertension and hyperlipidemia may have a 10-year cardiovascular mortality risk of 38%. Statin therapy could lower this to 34.6%, yielding a relative risk reduction of 9%, but the absolute reduction is just 3.4% . For a low-risk 45-year-old woman with mildly elevated cholesterol, the absolute benefit shrinks even further: from 1.4% to 1.3%, a mere 0.1% reduction .  Yet both cases are described under the same “relative reduction” umbrella. Figure 5. Relative vs. Absolute Risk Comparison, showing how identical relative reductions can mislead when applied across populations with very different baseline risks. While both patients receive the same relative reduction , their actual benefit diverges sharply . In low-risk individuals, up to 99 out of 100 may take the drug without any measurable advantage —a critical consideration often lost in the way data is framed. This underscores a central issue:  quoting relative statistics without absolute context creates a misleading impression of effectiveness. Phrases like “42% reduction in risk” may sound impressive, but in the absence of baseline risk, they distort both patient understanding and physician judgment . As shown in a BMJ study, when physicians were presented with the same data framed in different formats, they made significantly different clinical decisions, despite no change in the underlying evidence. ( 23 ) Presenting benefits in absolute terms , such as “reducing risk from 3 in 100 to 2 in 100”, supports clearer expectations, enhances informed consent , and prevents the exaggeration of modest treatment effects. Framing benefits exclusively in relative terms not only inflates perceived efficacy , but also encourages over-prescription , especially when applied indiscriminately across patient populations. Figure 6: Statistical vs Clinical Significance. This cartoon highlights how a 44% relative risk reduction in coronary death (from 5.4% to 3%) can mask a modest 2.4% absolute benefit, illustrating the gap between impressive statistics and meaningful patient outcomes . To ensure transparent and ethical communication, clinicians can present both relative and absolute risk figures to patients. Without this balance, we risk replacing informed consent with marketing rhetoric, and genuine care with numerical illusion. Why Relative Risk Reduction Misleads—and Misguides Marketing by Design: The Rhetoric of Relative Risk Relative Risk Reduction (RRR) remains one of the most abused metrics in clinical communication, statistically valid, yet strategically misleading. While it provides a percentage change between groups, it obscures the actual chance of benefit , especially when absolute effects are small. Take, for example, a therapy that reduces the risk of an event from 3 in 100 to 2 in 100. The absolute benefit is just 1%, but the RRR is 33%. This inflated figure sounds impressive but masks the reality  that 99 out of 100 people will not benefit. This distortion is not accidental . RRR is routinely used in advertisements, abstracts, and press releases to exaggerate clinical relevance . When absolute risk is mentioned at all, it is often relegated to fine print  or technical appendices, nowhere near the visual prominence or persuasive force of the headline relative reduction. This imbalance is designed to shape perception , not to inform. The inconsistency worsens when side effects are reported in absolute terms  (e.g., “1 in 100 may bleed”), while benefits are reported in relative terms  (e.g., “30% reduction in stroke risk”). This selective formatting creates an illusion of high benefit and minimal risk, undermining informed consent . Toward Honest Medicine: Ethical Communication of Risk To restore clarity and ethical balance in medical decision-making: Absolute Risk Reduction (ARR)  and Number Needed to Treat (NNT)  should be the primary metrics used in both patient and clinician communication. If RRR is used, Relative Risk Increase (RRI)  for harms must be presented with equal visibility and format. Promotional and guideline materials must avoid asymmetric framing , where benefits are bold and harms are buried.   In essence, RRR is not just misleading, it appears to be marketing by design . Its continued use without context confuses clinicians, misleads patients, and distorts shared decision-making . Honest medicine demands better.   Conclusion to Part 1 This section has highlighted how the foundational instruments of modern Evidence-Based Medicine, once envisioned as safeguards against anecdote and bias, are increasingly deployed in ways that obscure rather than clarify therapeutic value. Through multiple examples, we have shown how flawed trial designs, restrictive inclusion criteria, relative risk framing, and the rhetorical inflation of modest outcomes collectively distort both the scientific literature and clinical decision-making. These are not isolated deviations; they are systemic patterns. When modest absolute benefits are promoted using relative metrics, when harms are buried beneath surrogate endpoints, and when statistical abstractions displace patient-centered outcomes, the result is not just academic confusion, but compromised patient care. The findings presented here do not indict science itself, but rather how science is curated, presented, and consumed within a healthcare system shaped by competing incentives. For the practicing clinician, this raises critical questions: Are the metrics I’m using clinically meaningful? Is this recommendation based on real-world outcomes, or statistical proxies? For patients, it demands a renewed insistence on clarity: What is the actual benefit for someone like me? In Part 2, we follow this trajectory further, examining the structural forces that sustain and normalize these distortions: financial sponsorship, publication bias, regulatory blind spots, and the quiet erosion of physician judgment and patient voice. We also begin outlining a more grounded framework for medical certainty, rooted not only in analytical rigor, but in careful observation, reproducibility in real-world populations, and relevance to lived clinical experience. This foundation will ultimately set the stage for the deeper reforms explored in Part 3.. The question is no longer simply whether a study exists, but whether the evidence it claims to offer is trustworthy, applicable, and aligned with what matters most in the real world . Acknowledgment This article was written with AI assistance. All claims are supported by credible, peer-reviewed references, which were validated for accuracy and authenticity, ensuring scientific integrity throughout. In the event of any inadvertent errors, the responsibility lies with the AI, and corrections will be made promptly upon identification. I would like to express my sincere gratitude to Dr Marjorie Renfrow for her thoughtful review and invaluable feedback. Her expertise and guidance have played a pivotal role in refining and enhancing this article. Author’s Note on Scope and Intent. This article critiques methodological and systemic trends in medical research and does not allege misconduct by any specific individuals, institutions, or companies. All examples and analyses are drawn from publicly available data and peer-reviewed literature. REFERENCES Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med . 2014;174(4):588–595. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1832197 U.S. FDA. Enhancing the Diversity of Clinical Trial Populations — Guidance for Industry. 2020. https://www.fda.gov/media/134754/download Witham MD, Logan P, Brady MC. Assessment of representation of older adults in trials of pharmacologic interventions for ischemic heart disease: systematic review. Br J Clin Pharmacol . 2021. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14539 Tait AR, Voepel-Lewis T, Zikmund-Fisher BJ, Fagerlin A. Optimizing the presentation of research findings: the relative versus absolute risk debate. Cogn Res Princ Implic.  2023;8(1):10.   https://doi.org/10.1186/s41235-023-00520-y Dechartres A, et al. Reporting of harms in randomized controlled trials. PLoS Med . 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6377048/ Nickerson RS. Confirmation bias: a ubiquitous phenomenon in many guises. Review of General Psychology . 1998. https://www.researchgate.net/publication/286835865_Considering_confirmation_bias_in_design_and_design_research Ferreira-González I, et al. Problems with use of composite end points in cardiovascular trials: systematic review. BMC Medicine . 2007;5:6. https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0902-9 U.S. FDA. Multiple Endpoints in Clinical Trials Guidance. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials Button KS, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci . 2013. https://research-information.bris.ac.uk/en/publications/power-failure-why-small-sample-size-undermines-the-reliability-of Guyatt G, et al. The need for better reporting of harms. JAMA . 2004;292(3): 264–271. https://jamanetwork.com/journals/jama/fullarticle/194958 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients. Lancet . 1994. https://www.thelancet.com/pb/assets/raw/Lancet/pdfs/issue-10000/4s-statins.pdf Manson JE, Bassuk SS. Biomarkers in chronic disease: scientific and ethical implications. Am J Prev Med . 2003. https://pmc.ncbi.nlm.nih.gov/articles/PMC3653612/ Soomro GM, et al. SSRIs vs placebo for OCD. Cochrane Database Syst Rev . https://www.cochrane.org/CD001765/DEPRESSN_selective-serotonin-re-uptake-inhibitors-ssris-versus-placebo-for-obsessive-compulsive-disorder-ocd Khan A, et al. The effect of inclusion/exclusion criteria in antidepressant trials. Psychiatric Annals . 2008. https://pubmed.ncbi.nlm.nih.gov/18303940/ Fiore LD, et al. A guide to real-world effectiveness and safety studies. Clin Trials . 2011. https://pmc.ncbi.nlm.nih.gov/articles/PMC4632358/ Ntaios G, et al. Apixaban vs warfarin: real-world evidence. Stroke . 2018. https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.117.018395 Dwan K, et al. Systematic review of publication bias. Cochrane Database . https://s4be.cochrane.org/blog/2018/08/07/publication-bias-the-answer-to-your-research-question-may-be-sitting-in-somebodys-file-drawer/ Lexchin J, et al. Pharmaceutical industry sponsorship and research outcome. J Health Econ . 2003. https://www.journals.uchicago.edu/doi/10.1086/730383 Aberegg SK. Medical decision-making and the illusion of evidence. Medicines . 2021;8(7):36. https://www.mdpi.com/2305-6320/8/7/36 TheNNT.com . Statins for Heart Disease Prevention. https://thennt.com/nnt/statins-for-heart-disease-prevention-with-known-heart-disease/ Scandinavian Simvastatin Survival Study Group. Lancet . https://www.thelancet.com/pb/assets/raw/Lancet/pdfs/issue-10000/4s-statins.pdf Royal Australian College of General Practitioners. Statins and Risk Reduction. https://www1.racgp.org.au/newsgp/clinical/have-the-benefits-of-statins-been-overstated Covey J. A meta-analysis of risk reduction formats used in decision aids. BMJ . 2003;327(7417):741. https://www.bmj.com/content/327/7417/741 Bloch MH, et al. Meta-analysis of SSRI dose-response in OCD. Cochrane Database . https://www.cochrane.org/CD001765 Ntaios G, et al. Stroke. AHA Journals. https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.117.018395 Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition—multimorbidity. JAMA . 2012;307(23):2493–2494. https://pmc.ncbi.nlm.nih.gov/articles/PMC4083627/ 27. Alsheikh R, Alharthi S, Alzahrani A, Babtain F, Babtain F, Almalki A, et al. Prevalence of statin-associated muscle symptoms in Saudi Arabia: A cross-sectional study. Int J Gen Med.  2022;15:7817–26. doi:10.2147/IJGM.S378994. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9034880/ 28. University of Oxford. New study shows muscle pain not due to statins in over 90% of those taking treatment [Internet]. 2022 Aug 30 [cited 2025 May 26]. Available from: https://www.ox.ac.uk/news/2022-08-30-new-study-shows-muscle-pain-not-due-statins-over-90-those-taking-treatment 29. Ioannidis JPA. Why most published research findings are false. PLoS Med . 2005 Aug;2(8):e124 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0020124 Greenhalgh T, Howick J, Maskrey N. Evidence based medicine: a movement in crisis? BMJ . 2014;348:g3725. https://ww w.bmj.com/content/348/bmj.g3725

Dr. Qaisar J. Qayyum Chief Editor, Noor Journal of Complementary and Contemporary Medicine, Clinical Assistant Professor, Oklahoma, USA Email:   chiefeditor@njccm.org Comprehensive Summary of Phytochemical and Pharmacological Importance of Turmeric (Curcuma longa): A Review Turmeric (Curcuma longa L.), a member of the Zingiberaceae family, has been widely used in traditional medicine due to its rich phytochemical composition and medicinal properties. Indian turmeric, known for its high curcumin content, is particularly valued. The rhizomes, commonly referred to as Haldi, contain curcuminoids—curcumin, demethoxycurcumin, and bisdemethoxycurcumin—responsible for its vibrant yellow color and numerous health benefits. Turmeric is a well-known antiseptic with antimicrobial, anti-inflammatory, antioxidant, and anticancer properties. This review highlights its botanical classification, phytochemical constituents, pharmacological activities, and recent research trends. Introduction Medicinal plants have been an essential part of human therapy for centuries, providing bioactive compounds with therapeutic potential. According to the World Health Organization (WHO), around 80% of people in developing countries rely on medicinal plants for primary healthcare. Curcuma longa is a widely cultivated medicinal herb, particularly in India and China, where it plays a vital role in traditional healing systems. It has been used historically for gastrointestinal disorders, wound healing, diabetes management, and as a natural food preservative. In recent years, scientific studies have confirmed its pharmacological properties, including anti-inflammatory, antimicrobial, hepatoprotective, and anticancer effects. Taxonomy and Botanical Description • Kingdom: Plantae • Family: Zingiberaceae • Genus: Curcuma • Species: Curcuma longa Botanical Features:  Curcuma longa is a perennial, stemless herb that grows up to 1 meter in height. It has broad lanceolate leaves, yellow funnel-shaped flowers, and rhizomes that are oblong and often branched. The rhizomes contain essential bioactive compounds and serve as the primary source of turmeric powder. Phytochemical Constituents Turmeric contains a diverse array of phytochemicals, including: Curcuminoids • Curcumin (diferuloylmethane) – the principal bioactive compound (3-4%) • Demethoxycurcumin • Bisdemethoxycurcumin Essential Oils and Volatile Compounds • Turmerone • Ar-turmerone • Curcumene • Germacrone Other Bioactive Compounds • Alkaloids, flavonoids, tannins, glycosides, saponins, triterpenoids, and sterols • Minerals: calcium, iron, copper, manganese, phosphorus, sodium, and zinc • Vitamins: Ascorbic acid (Vitamin C), niacin (Vitamin B3), and beta-carotene (Vitamin A precursor) • Fixed oils and fatty acids The presence of these bioactive compounds contributes to turmeric’s extensive pharmacological applications. Preliminary Phytochemical Screening Various qualitative chemical tests were performed to detect different phytochemicals in turmeric extracts, confirming the presence of: • Alkaloids (via Mayer’s, Wagner’s, and Dragendorff’s tests) • Glycosides (Fehling’s and Keller-Killani tests) • Flavonoids (Shinoda and Alkaline Reagent tests) • Tannins, Saponins, and Triterpenoids (Gelatin and Salkowski tests) • Phenolic Compounds and Carbohydrates (Molish, Benedict’s, and Iodine tests) These tests establish the medicinal potential of turmeric in various formulations. Pharmacological Activities of Turmeric Anti-inflammatory Properties Curcumin is a potent anti-inflammatory agent that inhibits inflammatory mediators such as COX-2, LOX, TNF-α, and interleukins. Studies show that turmeric exhibits comparable efficacy to cortisone and phenylbutazone in reducing inflammation in conditions like arthritis and other inflammatory diseases. Animal studies indicate that curcumin significantly reduces edema and joint inflammation. Antimicrobial Effects Turmeric exhibits antimicrobial activity against various bacteria, fungi, and parasites. It has been effective against Plasmodium falciparum (malaria), Leishmania major, and Eimeria maxima (intestinal parasites in poultry). Additionally, turmeric oil has been found effective in treating dermatophyte and fungal infections. Antidiabetic Effects Turmeric plays a role in glucose metabolism and insulin regulation. Animal studies suggest that turmeric extracts enhance insulin secretion, reduce blood sugar levels, and prevent diabetes-related complications. Curcumin inhibits oxidative stress-induced damage to pancreatic beta cells, thereby improving glucose homeostasis. Antioxidant Properties Curcumin has strong antioxidant activity, comparable to vitamins C and E. It neutralizes free radicals and reduces oxidative stress, which is linked to aging, cardiovascular diseases, and neurodegenerative disorders. Hepatoprotective and Nephroprotective Effects Turmeric protects the liver and kidneys from toxic damage caused by chemicals such as carbon tetrachloride and aflatoxins. Studies show that curcumin enhances bile production and reduces liver enzyme levels, indicating improved liver function. Anti-cancer Properties Curcumin exhibits anticancer activity by inhibiting tumor growth and angiogenesis. Studies indicate that curcumin: • Suppresses tumor proliferation in colon, prostate, breast, and leukemia cancers • Induces apoptosis (programmed cell death) in cancerous cells • Acts as a chemopreventive agent in stomach tumors in Swiss mice Curcumin’s antioxidant properties also contribute to its ability to neutralize carcinogenic free radicals. Cardiovascular Benefits Turmeric helps reduce cholesterol levels, inhibit LDL oxidation, and prevent atherosclerosis. It also possesses anti-thrombotic properties, reducing the risk of blood clot formation. Animal studies demonstrate that turmeric extract lowers cholesterol and triglycerides in atherosclerotic rabbits. Gastrointestinal Effects Turmeric has been shown to: • Reduce ulcer formation • Increase gastric wall mucus • Improve pancreatic enzyme secretion • Reduce colitis and pancreatitis-induced inflammation A clinical study involving 25 patients with gastric ulcers showed that 48% experienced complete healing after turmeric treatment. Conclusion Turmeric (Curcuma longa) is a widely recognized medicinal plant with diverse therapeutic properties. Its bioactive compounds, particularly curcumin, contribute to its anti-inflammatory, antimicrobial, antioxidant, and anticancer effects. While turmeric has been extensively used in traditional medicine, further research, clinical trials, and standardization of its extracts are essential for its integration into modern pharmaceutical applications. Future research should focus on optimizing its bioavailability and exploring novel formulations to maximize its therapeutic benefits for human health. Acknowledgment This article was written with AI assistance. All claims are supported by credible, peer-reviewed references, which were validated for accuracy and authenticity. The AI synthesized information were reviewed by authors, ensuring scientific integrity throughout. In the event of any inadvertent errors, the responsibility lies with the AI/authors, and corrections will be made promptly upon identification. I would like to express my sincere gratitude to DrTahira Khalid, for their thoughtful review and invaluable feedback. Their expertise and guidance have played a pivotal role in refining and enhancing this article. Conflict of Interest Statement The author is the developer of a herbal formula and the owner of Dr. Q Formula/Insulinn LLC. However, this affiliation has not influenced the content, analysis, or conclusions of this article Reference Phytochemical and Pharmacological Importance of Turmeric.  Energy & Wetlands Research Group, Centre for Ecological Sciences, Indian Institute of Science, Bangalore.Available at: https://wgbis.ces.iisc.ac.in/energy/water/paper/Turmeric/Pub_%20Phytochemical%20and%20Pharmacological%20Importance%20of%20Turmeric%20(1).pdf

Aftab Ahmad, PhD — Professor, John Jay College of Criminal Justice, City University of New York (CUNY), New York, NY, USA Email: aahmad@jjay.cuny.edu Summary In this article, we review the current research in artificial intelligence (AI), especially in deep learning network algorithms, that can be instrumental in providing research data, privacy measures, early warning, detection and management of breast cancer. AI can complement the work of radiologists, oncologists, care takers, and researchers, among others. With the proposed use of cloud storage with AI, a life-threatening disease like breast cancer can get much needed assistance in handling the data by patients, providers, hospitals and researchers, in protecting patients’ privacy, and even in shortening the time for research findings to loop back to the patient. Introduction It will not be incorrect to say that medical research has seen a biased emphasis on gender-related health issues [18] . While it is easy to consider prevalence of male gender in research funding as a factor for this bias, the truth is that women's representation in medical research remains lower than the proportion of their population [23] . Studies on gender disparities against women reveal clearly a gap in not only them being seen by the same-gender physicians, but also in same diagnosis for the same symptoms, leading to denials of social security benefits for health-related disabilities [4] . However, the good news is that the number of female physicians continues to rise, especially in developed countries [21] . There is awareness on funding gap and research initiatives on women's health, particularly in breast cancer, but the results are neither too encouraging, nor applicable to women at all stages of life. Among menopausal women, mortality due to breast cancer has not decreased, as reported by the Women Health Initiative (WHI) [5] . With artificial intelligence (AI) making ripples in every field of life, one may wonder if its benefits for women's health will get a boost in retrospect to the traditional negligence. Studies have already been conducted, e.g., on ChatGPT [26]  on suitability of AI chatbots, in this paper regarding two of its versions (GPT3.5 and 4), on analyzing mammograms. While this study finds that both versions were short on meeting the gold standard for diagnosis, we leave this question open and instead address the more general question: what can be done to put AI in the service of women's health ? There is an underlying assumption here that AI is  beneficial. The reason for this assumption is that AI, particularly deep learning, has passed the initial test of its usability in the form of success of large language models (LLM)s [22] . What really needs to be determined is how it can benefit humanity in general, and women's health in particular. In this article, the focus is on the application of deep learning as a complementary diagnostic tool for women's health with a focus on breast cancer. In women, breast cancer constitutes 30% of all cancer diagnoses, making it the most prevalent form of cancer. A large number of women get regular mammograms because of family history. Sometimes controversaries arise due to false positives [3,27] , variation in detection abilities and interpretations of physicians [7] , and inability of computers to provide accurate diagnosis [8] , or just outright the efficacy of mammograms to correctly predict the onset of breast cancer [29]  due to any of the four reasons cited in this paper. Deep learning may already have advanced to the point that it can be helpful in early and accurate diagnosis. Of research, privacy, and early warning In this section, we will discuss the continuing need for using mammogram data for research, the problem of possible breaches in patient privacy, and the need for warning systems to alert potential patients and their providers of the new research findings. In the subsequent sections, we will discuss how deep learning can contribute as an assistive technology by helping in research, protecting patient privacy, and generating alerts to get early attention yet minimizing false positives. Research data for breast cancer Data for breast cancer can be collected in many ways, such as through a general trial, from specific groups, in which women from a race, or with given symptoms, or family history participate in the study, or even from an individual, in which case mammograms of the same person are used for research into pre-cursors, onset, detection, and prognosis of the disease. Data centers can be used for sharing data with researchers. A data breach in the data from public or specific population group can result in leakage of personally identifiable information (PII) unless data is properly anonymized. Differential privacy  is the state-of-the-art technology for privacy protection proposed to be applied to genome data [13] . However, differential privacy is not immune to data breaches [11] . For a single patient, it may be less challenging to protect the PII, but the amount of data may not be nearly as sufficient as needed to make accurate conclusions as reported in the individual participant data analysis for a study on the efficacy of digital breast tomosynthesis (DBT) in [17] . For each of the three cases, deep learning brings something new to the diagnostic methods and analysis. Thus, AI, in collaboration with cloud storage and cloud computing (a relatively mature technology) delivers solutions to make it easy for the patient and physician to handle data, to automate supply of research data with embedded privacy measures and create a warning system for immediate notification to the relevant parties. In the next Section, we present a scheme of integrating these technologies by identifying at which point AI integration happens. An AI-native, cloud-based data system for research and warning generation AI is nothing new. In fact, the American Association of Artificial Intelligence (AAAI) has been active since 1980 in the form of contributions to original research, AI applications and education. What has changed in the 21st century is a boost in the processing hardware and introduction of new algorithms in the realm of artificial neural networks (ANN)s, of which deep learning is a subset. Three types of ANN algorithms have particularly revolutionized the field. These are, generative adversarial network (GAN) popularly known from deep fakes, variational autoencoder (VAE) used to detect anomalies (outliers) in datasets, and the transformer used in natural language processing (NLP). These and other algorithms have made it possible to make AI integral to the design of medical data systems, be it related to storage of electronic medical records (EMR)s, privacy provision in data centers, design of alarm systems for the onset of diseases, or diagnoses. Figure 1 shows a schematic in which AI-native systems can serve multiple parties, including patients, physicians, researchers, and public health officials. As seen from Figure 1, data originating facilities (hospital/lab/clinic), patients, and researchers can all securely upload and access patient data to and on the cloud. Deep learning can be employed on the stored data to generate synthetic data (the so-called  fake data). The synthetic data has the same statistical properties as the original data but without any personally identifiable information (PII) in the data. This synthetic data can be shared with researchers. Patients and providers can access the actual data on the cloud that is not shared with researchers, thus protecting data from privacy breaches as well as eliminating the need for storing data on portable media, such as a USB or a CD. The data users for research may be required to share the results of their research by uploading the new research findings back to the cloud storage – as a payback for using data. Alarm systems can then inform providers about the potential impact of the new findings relevant to their patients either automatically or through secure access. In this schematic, (i) the data is always available to the patients, and all they need to do when changing providers is let their unique patient ID be known to the next provider, (ii) PII is never disclosed to data users who need data for research, and (iii) latest results of research loop back to the providers and through them to patients. Figure 1 also shows where exactly the AI algorithms will be used in this arrangement. Relevance to mammograms The system depicted in Figure 1 is particularly beneficial for working with mammograms because of several reasons. First, a large number of women are advised to get mammograms on a yearly basis, thus generating a series of data spread over many years. For such a series of mammograms year after year, the proposed system can automatically look for precursors of cancer and make it possible to set a warning using AI-based detection based on anomaly detection algorithms before it is too late for the patient. It must be noted though that more research is needed in determining the onset of an anomaly from precursor dataset, but the good news is that research is ongoing in this area. See for example [12]  for the efforts going on in this direction and its applications in various fields. In this paper, the authors present their deep learning solutions for an irregular time series data, which in fact may be a good fit for mammograms because of variation happening due to aging. What cloud storage provides is the cumulative data from a large number of subjects and all this (synthetic) data can be applied to a single AI model to make general conclusions. Secondly, in case of a single subject, deep learning provides methods to augment data by applying various techniques, as pointed out in [31] . These include commonly used techniques, such as regeneration of data using GANs, rotating, scaling, flipping, and cropping, and customizable algorithms that apply to given datasets (for example, augmenting part of image instead of the whole image, focus of various resolutions, etc.). One benefit of automating data feed to research is to first apply all data to reach a conclusion and then apply the single subject’s augmented data to determine the effectiveness of the multiple-subject data inference on a single subject. In these two scenarios, the use of synthetic data can completely mask private information. Thirdly, the success rate of cancer therapies can be determined by storing the therapeutic techniques against results as part of cloud storage. As pointed out in [28] , at each stage, there are multiple treatment choices. With the help of storage of datasets (images, biomarkers, techniques, frequencies, etc.) along with subject-specific data (age, race, family history, other biomarkers), the AI techniques can provide a customized treatment plan for a given set of conditions. Lastly, it is not very easy to manage mammograms of many years for a patient due to inconvenience and for the fact that people are moving a lot more due to jobs and other reasons. Having access to their mammograms, women do not have to go through the process of safe keeping and complex permission procedures. All they have to do is provide a special access key designed just for being given to the providers. The provider, by combining this access key with their own credentials, can access the images easily and securely. Next, we will say something regarding the relevant breakthroughs in deep learning. Leading relevant deep learning algorithms As mentioned earlier, hardware, in particular graphics processing unit (GPU), and the aforementioned new algorithms are vital to revolutionary surge in AI applications. These algorithms can be categorized into (i) generative AI, (ii) variational autoencoder (VAE), and (iii) transformer. VAE algorithms are types of generative too, but we keep them in a separate class due to their ability to detect outliers. Here is a brief description of these algorithms and their relevance to the topic of this article. Generative AI for privacy and data augmentation Generative AI has been made popular by the generative adversarial networks (GAN)s, but it is not limited to them. GAN was introduced by Goodfellow et al (see their later version in [9] ) by demonstrating that we can use noise to generate a target image by repetitively removing the error in the noise-generated image by comparing it with the real image (see Figure 2 for an illustration). As seen in Figure 2, a GAN is a cascade operation of two algorithms, a generator initially generating a random image from noise, and a discriminator comparing the generated image with the real image and generating the difference between the two as loss. In turn, the generator uses this loss to fix the generated images repeatedly until the discriminator can’t tell the difference between the real and the generated images. In the diffusion model, the real data is converted into noise with known diffusion (embedding) of noise at each time step of the algorithm. When the data starts appearing like complete noise, the reverse process (denoising) is possible to regenerate the original data. For mammograms, the data consists of images with some important properties, such as it is black and white, and the images from successive years must be treated as a time series, thus making the data a multivariate time series. In order to provide privacy to patients, the original data is used in a generative set up to generate synthetic data with the same statistical properties as the original data but without containing any personally identifiable information. Consequently, in any analysis except by human eye, synthetic data can be used, while the provider, such as a radiologist, can access the real data to confirm the results. In this way, generative AI can be employed in protecting patient privacy and for generating synthetic data for research. Synthetic data algorithms can also be used for data augmentation as described in [6] . Work on both aspects of generative AI for breast cancer research is ongoing. See for example [19]   for its application in data augmentation and [1]   for application of synthetic data in breast cancer research. Deep learning for anomaly detection (diagnosis) If a deep neural network algorithm is trained on a specific data type to simply recognize the input data on which it is trained, interesting things can happen. Such an algorithm, called autoencoder (AE) has many applications to identify new data in the form of hand-written text, audio-visual data and images. It also has the ability to identify anomalies by indicating that the input data is slightly different from what it was trained on! This ability can be generalized by employing statistical properties of input data and by using generated probabilistic data to match the training data. Such an algorithm can tell that something is abnormal in the input data. An example of such training is to create an VAE model trained on normal breast mammograms, so that when it is used with abnormal mammograms, it raises a red flag. Variational AE (VAE) was proven to be a valuable generative model by Kingma, (see, for example [14] ) that can be instrumental in identifying outliers in a dataset. Due to its utility in many areas, VAE work has been extended substantially and is also the subject of research for mammogram analysis, such as reported in [32] . Figure 3 shows the function of a generic VAE algorithm for anomaly detection. After this algorithm has been trained on normal data, the induced noise characteristics match those of the data. When it is used with abnormal  data, the matching does not work and data points outside the ‘normal’ can be identified. This can lead to detection of abnormalities in mammograms. Detection versus prediction Using data outliers is an old and mature technique and does not owe itself to AI or deep learning (see for example [15]  for a nice presentation on the topic). Deep learning has the promise to get very high accuracy and to reduce false positives. Besides, research is headed to using precursors instead of easily detectable outliers in not just mammograms, but also proteins and other molecular markers, including genetic data. Early warning could be made possible by analyzing datasets and training VAEs to identify possibility of onset , something on which a number of women invest a lot of time and money. See, for example [2]   for an account of various factors possibly linked to breast cancer that can assist in creating precursor datasets. Having mammograms, genetic and other molecular biomarkers stored as synthetic data in the cloud, being channelized for constant research can ultimately provide the required fuel to kickstart and produce results for VAE algorithms that will be able to send early warnings to providers and patients so that treatments can be planned before the cancer onset. Autogenerated reports  The third major algorithm mentioned above, that is, the transformer, has resulted in advancements in Large Language Models (LLM)s that have already made AI a household name. All major AI companies have transformer-based application programming interfaces (API)s used in a number of natural-language related applications. The innovation of transformer got a big boost from the simple idea that word- or sub-word-contexts are very important in natural languages [30]   resulting in modern LLMs. We are heading towards applying the LLMs to individual sectors including healthcare [20] . Its ultimate impact will be that the AI-based reporting systems will be customized to individual subjects and create alerts and on-demand reports for doctors and patients in any language. Work is ongoing specifically for breast cancer applications in this regard, as reported in [16, 24, 25] . Final word Application of AI, particularly of deep learning, in healthcare is unstoppable as it has a humongous potential. The question is ‘ can we make sure that women’s health is not ignored this time around ?’. The awareness of investing in research on women’s health, coupled with the fact that more and more women are joining the medical professions, means that it may be impossible to ignore their health. Granted that, how beneficial can AI technology be in providing relief to women in handling their data, keeping their privacy, and receiving timely warnings from new research. We contend through this article that all components are there for researchers, funding agencies and governments to invest in women’s health with AI developments. We took the example of breast cancer, a disease killing the largest proportion of women due to cancer worldwide, and second largest in USA. The goal is to show specific deep learning capabilities that relate to providing secure access to data through cloud, the ability to protect their privacy through generative AI, the ability to provide early warnings using precursor-based research, and detection capability along with convenience of auto-generated reports based on the natural language models. There is enough research work already in practice for investors and governments to fund AI for this purpose, and enough business potential for healthcare industry to rise to the occasion. Despite the recent strides in machine intelligence, human intelligence is irreplaceable. AI is an assistive technology with far-reaching benefits and its timely application can be a life saver. It cannot, however, replace human intelligence and the need for qualified supervision by a human is always going to be there. Acknowledgment I would like to express my sincere gratitude to Sharif Ahmad, Asad Khan and Dr. Qaiser Qayyum for their thoughtful review and invaluable feedback. Their expertise and guidance have played a pivotal role in refining and enhancing this article. References Aytar, B., & Gündüç, S. (2024). Generation of synthetic data using breast cancer dataset and classification with ResNet18. Karaelmas Fen ve Mühendislik Dergisi, 14 (3), 74–85. Berlin, L., & Hall, F. M. (2010). More mammography muddle: Emotions, politics, science, costs, and polarization. Radiology, 255 (2), 311–316. Brewer, N. T., Salz, T., & Lillie, S. E. (2007). Systematic review: The long-term effects of false-positive mammograms. Annals of Internal Medicine, 146 (7), 502–510. Cabral, M., & Dillender, M. (2024). Gender differences in medical evaluations: Evidence from randomly assigned doctors. American Economic Review, 114 (2), 462–499. Chlebowski, R. T., et al. (2024). Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women’s Health Initiative. Cancer . Dijkstra, R. (2024). The effects of data augmentation and synthetic data in breast cancer detection. Elmore, J. G., et al. (1994). Variability in radiologists’ interpretations of mammograms. New England Journal of Medicine, 331 (22), 1493–1499. Ganesan, K., et al. (2012). Computer-aided breast cancer detection using mammograms: A review. IEEE Reviews in Biomedical Engineering, 6 , 77–98. Goodfellow, I., et al. (2020). Generative adversarial networks. Communications of the ACM, 63 (11), 139–144. Goodfellow, I., et al. (2014). Generative adversarial nets. Advances in Neural Information Processing Systems, 27 . Haeberlen, A., Pierce, B. C., & Narayan, A. (2011). Differential privacy under fire. In 20th USENIX Security Symposium (USENIX Security 11) . Jhin, S. Y., Lee, J., & Park, N. (2023). Precursor-of-anomaly detection for irregular time series. In Proceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining  (pp. 917–929). Johnson, A., & Shmatikov, V. (2013). Privacy-preserving data exploration in genome-wide association studies. In Proceedings of the 19th ACM SIGKDD  (pp. 1079–1087). Kingma, D. P., & Welling, M. (2019). An introduction to variational autoencoders. Foundations and Trends® in Machine Learning, 12 (4), 307–392. Kriegel, H. P., Kröger, P., & Zimek, A. (2010). Outlier detection techniques. Tutorial at KDD, 10 , 1–76. Lee, J. J., et al. (2024). Automated identification of breast cancer relapse in CT reports using NLP. JCO Clinical Cancer Informatics, 8 , e2400107. Libesman, S., et al. (2022). Digital breast tomosynthesis vs digital mammography: A meta-analysis. Clinical Breast Cancer, 22 (5), e647–e654. Merone, L., et al. (2022). Sex inequalities in medical research: A systematic scoping review. Women’s Health Reports, 3 (1), 49–59. Moreno-Barea, F. J., et al. (2024). Data augmentation for breast cancer prognosis prediction. In International Conference on Computational Science  (pp. 19–27). Cham: Springer. Nerella, S., et al. (2024). Transformers and large language models in healthcare: A review. Artificial Intelligence in Medicine , 102900. Pickel, L., & Sivachandran, N. (2024). Gender trends in Canadian medicine and surgery: The past 30 years. BMC Medical Education, 24 (1), 100. Raiaan, M. A. K., et al. (2024). A review on large language models. IEEE Access . Rankin, J., et al. (2024). Women in the medical physics workforce. Int J Radiat Oncol Biol Phys. Sorin, V., et al. (2023). Applications of large language models in breast cancer care. medRxiv , 2023-11. Solarte-Pabón, O., et al. (2023). Transformers for extracting breast cancer information from Spanish clinical narratives. Artificial Intelligence in Medicine, 143 , 102625. Spuur, K., et al. (2024). Suitability of ChatGPT as a source of patient info for mammography. Health Promotion Practice , 15248399241285060. Tosteson, A. N., et al. (2014). Consequences of false-positive screening mammograms. JAMA Internal Medicine, 174 (6), 954–961. Trayes, K. P., & Cokenakes, S. E. (2021). Breast cancer treatment. American Family Physician, 104 (2), 171–178. Van Dijck, J. A., et al. (1993). Detectability of breast cancer in screening programs. Cancer, 72 (6), 1933–1938. Vaswani, A., et al. (2017). Attention is all you need. Advances in Neural Information Processing Systems . Wang, J., & Perez, L. (2017). Effectiveness of data augmentation in deep learning. Convolutional Neural Networks for Visual Recognition, 11 , 1–8. Zhang, Z., et al. (2024). Unsupervised hybrid framework for anomaly detection in screening mammograms. arXiv preprint arXiv:2409.11534 .

Hanna Saadah, MD, FACP — Professor Emeritus of Internal Medicine, specializing in Infectious Diseases and Geriatrics Professor Saadah I was ten-years old, playing with my friends at hunting lizards in the hills around my Lebanese hometown.  We were using slingshots that we had made out of inner tubes of old car tires.  One of my friends, Nazeeh, could not use the slingshot because holding and pulling on it made the warts on his fingers bleed. I asked my gynecologist mother and surgeon father to help Nazeeh.  They took him to a dermatologist in Tripoli, who treated him three times, but the warts got worse instead of better.  I complained to my old aunt who suggested seeking help from Elias, the village wart healer, alcoholic, and dairy farmer. We walked all the way to Elias’s dairy, tucked in the hills.  He only had three cows, and when we showed up, he looked at us with bulging eyes and said, “Who has the warts?”  We pointed to Nazeeh.  “You have a lot of warts,” he said after examining Nazeeh’s hands.  “Go down to the creek and fetch me a big-fat frog,” he ordered, addressing us all. When we could not find a frog, he got up from his milking stool, went down to the creek, and caught a frog that was hiding under the creek’s edge.  Then, he pasted the frog’s belly slime on Nazeeh’s warts, told him not to wash his hands, and asked us to return the next day. He did the same thing the next day, the third day, and asked us to return in a week.  When we returned, the warts had dried and fallen off.  When I told my mother and father, they just said that wars are known to come and go for no reason. Forty years later, when I became an infectious disease specialist, a research article appeared in one of my infectious-disease journals.  The article provided evidence that frog-belly slime has strong antimicrobial and antiviral properties. The memory of Elias, curing Nazeeh’s warts with frog-belly slime, brought tears to my eyes.  Elias, my hometown’s wart healer, was ahead of his time by about forty years. White-Willow Bark ( Salix alba) was known to help fever and pain, for more than 5 thousand years, before Charles Frédéric Gerhardt in 1853 discovered that it contained aspirin.  A 5000 BC stone tablet from Ur, Sumer, stated that White-Willow Bark   had   Analgesic, Antipyretic, Anti-inflammatory properties.  Smallpox vaccine was developed by dairy farmers when their milkmaids did not develop cow pox on their hands. Often, laymen’s observations can pave the way to scientific discoveries.

Dr. Qaisar J. Qayyum Chief Editor, Noor Journal of Complementary and Contemporary Medicine, Clinical Assistant Professor, Oklahoma, USA Email:   chiefeditor@njccm.org Introduction Turmeric (Curcuma longa), a plant native to Southeast Asia, has been a cornerstone of traditional medicine for centuries, particularly in Ayurvedic and Chinese medicinal systems. The golden-yellow spice is renowned for its diverse pharmacological properties, primarily attributed to its active constituent, curcumin. In recent decades, extensive scientific research has focused on its anti-inflammatory, analgesic, antioxidant, and immunomodulatory effects. Given the growing preference for natural alternatives over synthetic drugs, turmeric and curcumin have gained prominence in treating chronic inflammatory conditions, pain disorders, and metabolic syndromes. Despite compelling laboratory and preclinical data, clinical applications remain under scrutiny due to bioavailability concerns. However, technological advancements in drug formulation, such as liposomal encapsulation, nanoformulations, and curcumin-phospholipid complexes (e.g., Meriva®, Longvida®, Theracurmin®), are overcoming these limitations. This review delves deeply into the clinical relevance of turmeric and curcumin, providing a comprehensive analysis of its efficacy, mechanisms of action, and commercial applications. We also explore related patents, demonstrating its growing impact in the pharmaceutical and nutraceutical industries. Mechanisms of Action: How Curcumin Works Curcumin’s broad therapeutic efficacy is linked to its ability to modulate multiple cellular signaling pathways involved in inflammation, oxidative stress, apoptosis, and immune regulation. Anti-Inflammatory Pathways Chronic inflammation is a hallmark of numerous diseases, including arthritis, inflammatory bowel disease (IBD), cardiovascular diseases, neurodegenerative disorders, and cancer. Curcumin combats inflammation through: Inhibition of Nuclear Factor-kappa B (NF-κB): NF-κB is a master regulator of inflammation, controlling the expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). Curcumin suppresses NF-κB activation, thereby reducing cytokine production and tissue damage. Cyclooxygenase-2 (COX-2) and Lipoxygenase (LOX) Suppression: These enzymes catalyze the production of inflammatory prostaglandins and leukotrienes. Curcumin acts as a natural COX-2 inhibitor, providing anti-inflammatory benefits similar to NSAIDs but without gastrointestinal side effects. Mitogen-Activated Protein Kinase (MAPK) Pathway Regulation: Curcumin modulates MAPK signaling, which plays a critical role in cell survival, apoptosis, and immune responses. Antioxidant and Free Radical Scavenging Activity Oxidative stress contributes to inflammation and cellular damage in chronic diseases. Curcumin neutralizes reactive oxygen species (ROS) and enhances antioxidant defenses by upregulating: Superoxide dismutase (SOD) Glutathione peroxidase (GPx) Catalase (CAT) Nuclear factor erythroid 2–related factor 2 (Nrf2), a master regulator of antioxidant genes Immunomodulatory Effects Curcumin exhibits immune-balancing effects, particularly in autoimmune diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), and psoriasis. It enhances regulatory T cell (Treg) activity, inhibits T helper 17 (Th17) differentiation, and reduces autoimmune-driven inflammation. Curcumin in Arthritis Management Clinical Evidence Curcumin’s role in arthritis has been extensively studied in clinical trials, showing efficacy comparable to NSAIDs. A meta-analysis of randomized controlled trials (RCTs) confirmed that curcumin (1,000–1,500 mg/day) significantly reduced pain and improved joint function in osteoarthritis (OA) and rheumatoid arthritis (RA) patients. A 3-month trial using Meriva® (a curcumin-phosphatidylcholine complex) in 50 OA patients demonstrated a 58% reduction in joint pain and improved mobility. A double-blind RCT in RA patients comparing curcumin (1,200 mg/day) to diclofenac (NSAID) found curcumin to be equally effective in reducing joint inflammation without adverse effects. In Vivo and In Vitro Studies Animal models of arthritis showed curcumin reduces synovial inflammation, inhibits cartilage degradation, and prevents bone loss. In vitro studies confirmed curcumin suppresses inflammatory cytokines (IL-1β, TNF-α) in chondrocytes, protecting against cartilage degeneration. Patents and Commercial Formulations Curcumin-based joint health supplements such as Flexofytol®, Longvida®, and Theracurmin® have been patented for arthritis relief. Pharmaceutical companies are developing curcumin-nanoparticle injections for targeted intra-articular therapy. Curcumin in Skin Disorders and Dermatology Clinical Evidence A clinical trial in psoriasis patients found that topical curcumin gel led to a 90% improvement in symptoms. Curcumin was shown to reduce radiation-induced dermatitis in breast cancer patients undergoing radiotherapy. Nano-emulsified curcumin formulations improved wound healing and collagen synthesis. Mechanism of Action Curcumin blocks phosphorylase kinase, an enzyme involved in psoriasis pathogenesis, and reduces pro-inflammatory mediators (IL-6, TNF-α, IFN-γ) in keratinocytes. Patents in Skincare Curcumin is a key ingredient in patented anti-aging creams, sunscreens, and wound-healing formulations, due to its UV-protective and collagen-enhancing properties. Curcumin in Inflammatory Bowel Disease (IBD) Clinical Trials A 6-month study in ulcerative colitis (UC) patients found that curcumin (2 g/day) significantly reduced disease activity and relapse rates. In Crohn’s disease, curcumin improved symptoms and lowered inflammatory markers. Mechanisms of Action Reduces gut inflammation by inhibiting NF-κB and IL-1β Enhances gut microbiota balance Protects intestinal mucosa from oxidative damage Patents in Gastroenterology Curcumin is now included in patented gastro-resistant formulations (e.g., EnteroCurcumin®) for IBD and colitis treatment. Curcumin in Pain Management Clinical Evidence RCTs in knee osteoarthritis showed curcumin (1,000 mg/day) was as effective as ibuprofen for pain relief. Postoperative pain trials demonstrated curcumin reduces opioid dependence. Menstrual pain relief studies found curcumin significantly alleviates dysmenorrhea. Mechanisms of Action Inhibits transient receptor potential (TRP) ion channels involved in pain perception Enhances endorphin release Reduces prostaglandin synthesis Patents in Pain Relief Curcumin-based topical analgesic gels, oral supplements, and transdermal patches are widely patented for chronic pain and neuropathy. Conclusion: The Future of Curcumin in Medicine The clinical applications of turmeric and curcumin are vast and well-supported by scientific evidence. From arthritis and IBD to pain management and dermatology, curcumin offers a natural, effective alternative to synthetic drugs. However, bioavailability remains a challenge. Advanced liposomal, nanoparticle, and micellar formulations are rapidly transforming curcumin into a mainstream therapeutic agent. FDA-approved curcumin derivatives are on the horizon, and future research will likely cement its place in modern medicine. For clinicians, researchers, and pharmaceutical innovators, curcumin represents a powerful natural solution with immense potential in treating inflammatory diseases. Acknowledgment This article was written with AI assistance. All claims are supported by credible, peer-reviewed references, which were validated for accuracy and authenticity. The AI synthesized information were reviewed by authors, ensuring scientific integrity throughout. In the event of any inadvertent errors, the responsibility lies with the AI/authors, and corrections will be made promptly upon identification. I would like to express my sincere gratitude to DrTahira Khalid, for their thoughtful review and invaluable feedback. Their expertise and guidance have played a pivotal role in refining and enhancing this article. Conflict of Interest Statement The author is the developer of a herbal formula and the owner of Dr. Q Formula/Insulinn LLC. However, this affiliation has not influenced the content, analysis, or conclusions of this article Reference Razavi BM, Ghasemzadeh Rahbardar M, Hosseinzadeh H. A Review of Therapeutic Potentials of Turmeric (Curcuma longa) and Its Active Constituent, Curcumin, on Inflammatory Disorders, Pain, and Their Related Patents.   Phytotherapy Research.  2021 Dec;35(12):6489–6513. doi: 10.1002/ptr.7224

Dr. Qaisar J. Qayyum Chief Editor, Noor Journal of Complementary and Contemporary Medicine, Clinical Assistant Professor, Oklahoma, USA Email:   chiefeditor@njccm.org Abstract Honey has long been celebrated for its medicinal and nutritional properties, deeply rooted in religious and cultural traditions. The Qur'an extols its virtues as a source of healing (The Holy Qur'an 16:69) [3], and honey remains a cornerstone of complementary medicine. However, modern medical recommendations advise against honey consumption in infants under one year due to its association with infant botulism, a rare but serious condition. This article critically examines the actual risk of infant botulism from honey consumption in the U.S., comparing it to other health risks such as hypoglycemia-related damage, food allergies, and accidents. The analysis reveals that the risk is minimal and vastly overshadowed by other prevalent threats to infant health, supporting a balanced approach that respects both tradition and science. Introduction Honey holds a unique place in human history as a symbol of nourishment and healing. Religious texts like the Qur'an refer to honey as a source of "healing for mankind" (The Holy Qur'an 16:69) [3]. Proverbs 16:24 states, "Gracious words are like a honeycomb, sweetness to the soul and health to the body." Traditional medicine systems, including Ayurveda and Chinese medicine, have used honey to treat ailments ranging from wounds to gastrointestinal disorders. Despite its recognized benefits, modern medical guidelines caution against giving honey to infants under one year due to the risk of Clostridium botulinum  spore ingestion, which can lead to infant botulism (AAFP, 2002) [1]. This article bridges the gap between these perspectives by evaluating the theoretical and actual risk of infant botulism from honey, placing it in context with other risks to newborn health. This analysis aims to provide a comprehensive understanding of honey's role in neonatal care. Infant Botulism: Pathophysiology and Epidemiology Infant botulism occurs when Clostridium botulinum spores colonize the immature gastrointestinal tract, producing a neurotoxin that blocks acetylcholine release at neuromuscular junctions. Symptoms include constipation, hypotonia, poor feeding, and respiratory difficulties, with severe cases requiring mechanical ventilation. Recovery is typically complete with supportive care, and the case-fatality rate is less than 2% (AAFP, 2002) [1]. Epidemiology: The CDC (2019) [2] reports that infant botulism constituted 71% of all botulism cases in the U.S. in 2019, with 152 cases reported. Based on CDC data, the overall risk of developing infant botulism from all causes is approximately 1 in 24,000 live births annually. AAFP (2002) [1] states that approximately 15% of infant botulism cases have a history of honey consumption. According to the same source, there were over 250 cases of infant botulism annually at the time. Applying the 15% estimate to this number, approximately 38 cases per year could be linked to honey ingestion based on AAFP data. Comparing Risks: Infant Botulism vs. Other Threats To contextualize the risk of infant botulism, it is essential to compare it to other significant risks to newborn and child health: Infant Botulism: The overall risk from all sources is 1 in 24,000 live births annually (CDC, 2019) [2]. The risk of developing infant botulism specifically from honey, based on AAFP estimates, would be approximately 1 in 97,000 live births annually (AAFP, 2002) [1]. Neonatal Hypoglycemia-Related Damage: High-risk infants, such as those born preterm or to diabetic mothers, face a much greater risk of 1 in 1,000, or 0.1 %, of permanent neurodevelopmental damage if hypoglycemia is not managed promptly (PubMed, 2000) [4]. Childhood Food Allergies: Food allergies affect 7.6% of children, or approximately 1 in 13 (PubMed, 2018) [8]. Transportation-Related Accidents: The annual risk of being involved in a transportation accident is significantly higher than that of botulism (Injury Facts, 2022) [7]. Fig 1:   Encouragingly, this graph shows that the risk of infant botulism from honey is more than 100 times lower than the risk of neonatal hypoglycemia. Given this contrast, especially in underserved regions, honey may serve as a readily available, energy-rich intervention to prevent early hypoglycemia in newborns—supporting its cautious re-evaluation in neonatal care protocols where immediate clinical support is limited. Honey’s Broader Applications While honey consumption is discouraged in infants, its therapeutic benefits in older populations and other contexts are well-documented: Antimicrobial and Antifungal Properties: Studies demonstrate honey’s efficacy in wound healing and fungal infections, such as vaginal candidiasis. A clinical trial showed that honey gel was as effective as clotrimazole cream, offering a natural alternative with fewer side effects (PMC, 2020) [5]. Traditional and Complementary Medicine: Honey has been used for centuries in gastrointestinal health, immune support, and as an adjunct therapy for bacterial infections (PubMed, 2002) [6]. Balancing Tradition and Modern Guidelines The prohibition of honey in infants under one year is maybe based on sound epidemiological evidence. However, it is very clear that the absolute risk is minimal , especially when compared to other risks such as neonatal hypoglycemia or food allergies. This raises the question of whether current public health messaging about honey might benefit from a more nuanced approach. From a practical standpoint, caregivers can be educated about the safety of honey introduction while respecting its cultural and religious significance. Honey’s role in complementary medicine can continue to be explored, particularly in older children and adults. Conclusion Honey remains a symbol of healing and nourishment, celebrated in religious and traditional contexts. While the modest risk of infant botulism justifies caution, the absolute incidence is extremely low, particularly when compared to other risks such as neonatal hypoglycemia and food allergies. By contextualizing these risks, we can adopt a balanced approach that honors honey’s historical significance while ensuring the safety of infants. Further research and public education are essential to harmonize tradition and science in neonatal care. Acknowledgment This article was written with AI assistance. All claims are supported by credible, peer-reviewed references, which were validated for accuracy and authenticity. The AI synthesized information were reviewed by authors, ensuring scientific integrity throughout. In the event of any inadvertent errors, the responsibility lies with the AI/authors, and corrections will be made promptly upon identification. I would like to express my sincere gratitude to Dr Samara Khalid  and for their thoughtful review and invaluable feedback. Their expertise and guidance have played a pivotal role in refining and enhancing this article. Conflict of Interest Statement The author is the developer of a herbal formula and the owner of Dr. Q Formula/Insulinn LLC. However, this affiliation has not influenced the content, analysis, or conclusions of this article References American Academy of Family Physicians (AAFP). Infant Botulism: Clinical Features and Diagnosis.   American Family Physician.  2002;66(7):1388–1392. Available at: https://www.aafp.org/pubs/afp/issues/2002/0401/p1388.html#afp20020401p1388-b5 Centers for Disease Control and Prevention (CDC). National Botulism Surveillance Summary.  2019. Available at: https://www.cdc.gov/botulism/php/national-botulism-surveillance/2019.html The Holy Qur’an , Surah An-Nahl, 16:69. Cornblath M, Ichord R. Hypoglycemia in the Neonate.   Seminars in Perinatology.  2000;24(2):136–149. Available at: https://pubmed.ncbi.nlm.nih.gov/10805169/ Al-Waili N, Salom K, Al-Ghamdi A. Efficacy of Topical Application of Honey Gel on Fungal Infection.   J Dermatol Treat.  2020. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7492967/ Arnon SS, Schechter R, Inglesby TV, et al. Botulinum Toxin as a Biological Weapon: Medical and Public Health Management.   JAMA.  2001;285(8):1059–1070. Available at: https://pubmed.ncbi.nlm.nih.gov/12432974/ National Safety Council. Deaths by Transportation Mode.   Injury Facts.  2022. Available at: https://injuryfacts.nsc.org/home-and-community/safety-topics/deaths-by-transportation-mode/ Gupta RS, Warren CM, Smith BM, et al. The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States.   Pediatrics.  2018;142(6):e20181235. Available at: https://pubmed.ncbi.nlm.nih.gov/30455345/

Midhat Qamar, MBBS Noor Hospital, Qadian, India This journal, NOOR (light) , is proudly named after Hadrat Hakeem Maulana Nooruddin (1841–1914), the first Caliph of the Ahmadiyya Muslim Community, in honor of his unparalleled contributions to the fields of medicine and holistic healing . As both a scholar and physician, Hadrat Noor-ul-Deen's legacy embodies the integration of traditional medicine with spiritual well-being, making him a role model for healthcare practitioners worldwide. His exemplary service to humanity and visionary approach to complementary medicine continue to inspire future generations. A Master of Traditional and Complementary Medicine Hadrat Hakeem Noor-ul-Deen was widely recognized for his expertise in Unani/Hikmat medicine, an ancient system of medicine rooted in the Greco-Arabic tradition. His medical practice was grounded in a thorough understanding of herbal remedies, natural healing techniques, and the balance of bodily humors. Trained under renowned practitioners in India and the Arab world, he combined theoretical knowledge with practical experience to treat a wide range of conditions, from respiratory issues to digestive disorders and mental health challenges. One of his most significant contributions to the field is Bayaz-e-Noor-ul-Deen (The Notebook of Nooruddin), a compendium of medical formula s that offers a systematic approach to treating various ailments. The work serves as a valuable resource for Hikmat practitioners, providing remedies that are both accessible and effective. His holistic view of health, which emphasizes the interconnection between the physical, mental, and spiritual aspects of well-being, aligns closely with modern integrative medicine and continues to influence current practices ( 1 ). Clinical Practice and Contributions to Healthcare Throughout his career, Hadrat Nooruddin treated patients from all walks of life, offering care based on his deep understanding of medical principles. His role as Royal Physician to the Maharaja of Jammu and Kashmir and ruler of Rampur (6) further showcased his medical expertise and placed him in a unique position to serve diverse communities ( 4 , 5 ). However, despite his esteemed position, he remained deeply committed to serving the common people, providing treatment to those who could not afford care. His practice was marked by humility, and he never demanded payment for his services, believing instead in offering care as a means of service to humanity ( 6 ). Hadrat Nooruddin’s medical methods were rooted in a strong belief in natural remedies and preventive care. He was known for his ability to diagnose illnesses accurately and prescribe effective treatments without reliance on expensive remedies. His approach to patient care, which combined medical knowledge with a deep understanding of human nature, set him apart as a physician deeply dedicated to improving the lives of his patients. Innovations in Public Health and Education Beyond his individual clinical practice, Hadrat Nooruddin made significant contributions to public health. He founded Noor Hospital in Qadian, India, which provided essential healthcare services to underserved communities, ensuring that medical care was accessible to those who might otherwise be excluded. His efforts in establishing affordable healthcare options have had a lasting impact on public health, particularly in rural and underserved regions ( 3 ). In addition to his clinical work, Hadrat Nooruddin had extreme love for books, and was a passionate educator. He promoted the importance of hygiene, preventive healthcare, and the use of natural remedies to maintain overall health. His writings and teachings, including his medical compendium Bayaz-e-Noor-ul-Deen , have influenced generations of practitioners who seek to integrate traditional healing methods with modern medical practices ( 2 ). Through these efforts, he played a key role in preserving valuable traditional knowledge while adapting it to the needs of contemporary healthcare. Holistic Approach to Healing and Compassionate Care Hadrat Nooruddin’s philosophy of medicine was rooted in compassion, humility, and service to others. He was known for his generosity, offering free medical care to the impoverished and ensuring that no one was turned away due to financial constraints. His approach to healthcare emphasized the importance of treating patients with dignity and respect, regardless of their social or economic status. He was also known for his emotional intelligence and the ability to understand the psychological and emotional needs of his patients. His compassionate approach to care, combined with his deep understanding of medical practices, made him an exceptional healer, respected by both peers and patients alike. Through his writings, clinical work, and educational efforts, Hadrat Nooruddin has left a lasting legacy that continues to inspire healthcare practitioners who seek to offer compassionate, effective, and accessible care to all individuals. Hadrat Hakeem Nooruddin Conclusion: Honoring a Legacy of Compassionate Healing Hadrat Hakeem Maulana Nooruddin's life is a testament to the profound impact that traditional medicine, grounded in compassion and wisdom, can have on the health and well-being of individuals and communities. His contributions to the fields of Unani/Hikmat, preventive healthcare, and public health continue to inspire those who seek to improve the lives of others through integrative and patient-centered care. It is in recognition of his extraordinary legacy that NOOR  journal carries forward his mission to share knowledge, compassion, and healing with the world. May his work continue to guide us in the pursuit of better healthcare for all. Acknowledgment This article was written with AI assistance. All claims are supported by credible, peer-reviewed references, which were validated for accuracy and authenticity. The AI synthesized information were reviewed by authors, ensuring scientific integrity throughout. In the event of any inadvertent errors, the responsibility lies with the AI/authors, and corrections will be made promptly upon identification. I would like to express my sincere gratitude to Dr Qaisar Qayyum, Dr Tahira Khalid and , Dr Shaista azhar for their thoughtful review and invaluable feedback. Their expertise and guidance have played a pivotal role in refining and enhancing this article. Conflict of Interest Statement The main author Dr Midhat has not reported any conflict of interest. Dr Qayyum is the developer of a herbal formula and the owner of Dr. Q Formula/Insulinn LLC. However, this affiliation has not influenced the content, analysis, or conclusions of this article References Ahmad MM. Hazrat Hakeem Maulana Nooruddin.  Translated by Naseer Ahmad Bani, Calcutta. Available at: https://www.alislam.org/articles/hazrat-hakeem-maulana-nooruddin/ Nooruddin H. Bayaz-e-Nooruddin (The Notebook of Nooruddin).  Compiled by Hazrat Hakeem Maulana Nooruddin. Available at: https://archive.org/details/ByazENurudin/page/n41/mode/2up Quraishi AM. Personal Accounts of Hazrat Nooruddin.  Available at: https://lajna.org.uk/wp-content/uploads/2020/06/Hazrat-Khalifatul-Masih-I-ra.pdf Historical Accounts of Hazrat Nooruddin’s Service to the Maharaja of Kashmir.  Al Hakam. Available at: a) https://www.alhakam.org/formative-years-of-hazrat-hakim-maulvi-nuruddin-part-ii/  b) https://www.alhakam.org/photograph-of-hazrat-hakeem-maulvi-nooruddin-khalifatul-masih-i/ Hadhrat Maulvi Haji Hakim Nuruddin.  True Islam. Available at: https://trueislam.com/leadership/the-first-khalifa-ra/ Khalifatul Masih I.  AMJ International. Available at: https://www.amjinternational.org/khilafat/khalifatul-masih-i/

Dr Syed Mansoor Ahmad, MBBS Integrative Medical Practitioner: Bridging Allopathy and Homeopath How Homeopathic Remedies Work The foundational principle of homeopathy lies in understanding how a remedy stimulates the body’s natural healing response. To comprehend this mechanism, it is essential to first recognize how the human body reacts to external stimuli. The Body’s Natural Defense Mechanisms In a state of health, the human body maintains internal balance (homeostasis) through various feedback systems (1). When exposed to external influences—whether environmental, infectious, or otherwise—the body responds as a unified system. This response involves activating different defense mechanisms to address the disturbance. For instance, if an infectious agent invades, the immune system recognizes it and initiates a specific, multi-layered defense process. Symptoms arising from this response—fever, fatigue, localized inflammation, or pain—reflect the body’s collective effort to neutralize the invader. These symptoms represent the  totality of the body’s response,  a concept central to homeopathy. Examples of the Body’s Opposite Reactions The body’s ability to counteract stimuli can be observed in everyday situations: 1. Cold Water Experiment:  When you immerse your hand in ice-cold water, it becomes painful, prompting you to withdraw it. Subsequently, the hand warms up and may feel even hotter than the other hand. This heightened warmth is a compensatory reaction to the cold stimulus. 2. Opium Withdrawal in Habitual Users:  Opium slows bowel movements and has a sedative effect. When it is abruptly stopped, the body compensates with restlessness, anxiety, and an increase in bowel activity, often resulting in diarrhea. This demonstrates the body’s tendency to react oppositely to an external stimulus (2). These examples highlight the concept of the body’s  secondary response , which is often opposite to the initial stimulus. This principle is instrumental in understanding how homeopathy facilitates recovery. Homeopathic Proving and Symptom Totality Homeopathic remedies are derived from substances “proved” on healthy individuals. In proving, participants take a specific remedy repeatedly until they exhibit distinct physical, emotional, and mental symptoms (3). This creates an artificial disease state, with a comprehensive set of symptoms that are meticulously documented in  materia medica . Each remedy, therefore, corresponds to a unique “symptom totality” or sickness picture. When a patient presents with a disease whose symptoms match those produced by a particular remedy during proving, that remedy is selected. How Homeopathic Remedies Stimulate Healing When a remedy matching the patient’s symptom totality is administered, it acts as a signal to the body’s defense system, mimicking the disease and prompting a healing response. The body reacts oppositely to the remedy’s primary action, initiating a natural recovery process. This recovery involves the activation of the body’s auto-regulatory mechanisms, restoring health holistically (3). Preparation of Homeopathic Remedies Homeopathic remedies are prepared through a process of  dilution and potentiation . This involves repeatedly diluting the original medicinal substance and vigorously shaking (succussing) the solution. This method is believed to enhance the latent properties of the substance, enabling it to elicit subtle mental and physical symptoms during proving (3). These remedies, when administered, impacts the central consciousness, which mounts a secondary reaction leading to natural healing . The symptoms recorded during proving help guide practitioners in selecting the remedy that most closely matches the patient’s symptom profile. Conclusion Homeopathy is built on the principle of “like cures like” and the body’s natural tendency to heal itself. By carefully selecting remedies that correspond to the patient’s symptoms, homeopathy aims to stimulate a secondary response that restores balance and promotes recovery. This individualized approach ensures that healing addresses not just physical symptoms, but also mental and emotional well-being. The classical version of homeopathy “like cures like “is proved on humans by Dr Hahnimann and his prime followers . The subsequent versions of homeopathy like mixing the remedies may have some clinical benefits some in patients but still lack the original provings in cohort of humans beings. Acknowledgment This article was written with AI assistance. All claims are supported by credible, peer-reviewed references, which were validated for accuracy and authenticity. The AI synthesized information were reviewed by authors, ensuring scientific integrity throughout. In the event of any inadvertent errors, the responsibility lies with the AI/authors, and corrections will be made promptly upon identification. I would like to express my sincere gratitude to DR Qaisar Qayyum , DrTahira Khalid and Doctor Zainab Qadeer Doctor Homeopath for their thoughtful review and invaluable feedback. Their expertise and guidance have played a pivotal role in refining and enhancing this article. which were validated and and Conflict of Interest Statement Dr Mansoor do not report any conflict of interest. References Guyton AC, Hall JE. Textbook of Medical Physiology.  13th ed. Philadelphia: Elsevier; pp. 3–10. Katzung BG. Basic & Clinical Pharmacology.  12th ed. New York: McGraw-Hill Education; p. 555. Kent JT. Lectures on Homeopathic Philosophy.  New Delhi: B. Jain Publishers.